

Table of Alberta Immunization Policy (AIP) Updates

Revision Date: October 4, 2024

The updates are listed in chronological order, and date back to August 25, 2016. For up-to-date biological product start and end dates and historical program notes prior to August 25, 2016, see [Alberta Immunization Program History](#).

The 'Date' in the third column refers to when an update is made to the AIP (e.g., implementation date, policy revision date).

Section	Updates	Date
History of Immunization in Alberta – Alberta Immunization Program Changes	<ul style="list-style-type: none"> End date added for Novavax Nuvaxovid XBB.1.5 Start dates added for Moderna Spikevax KP.2 and Pfizer BioNTech KP.2 Start date added for Abrysvo™, Respiratory Syncytial Virus (RSV) Start date added for Influenza Inactivated Quadrivalent: Flucelvax® 	October 1, 2024
Biological Products – COVID-19 – Moderna Spikevax	<ul style="list-style-type: none"> September 17, 2024 – Licensed for use in Canada. October 2024 – Implemented in Alberta. 	October 1, 2024
Biological Products – COVID-19 – Pfizer BioNTech	<ul style="list-style-type: none"> September 24, 2024 – Licensed for use in Canada. October 2024 – Implemented in Alberta. 	October 1, 2024
Special Situations for Immunization – Immunization recommendations for transplant candidates and recipients – Adult HSCT	<ul style="list-style-type: none"> Addition of use of high-dose influenza and RSV vaccine. 	September 30, 2024
Special Situations for Immunization – Immunization recommendations for transplant candidates and recipients – Adult SOT	<ul style="list-style-type: none"> Addition of use of high-dose influenza and RSV vaccine. 	September 30, 2024
Biological Products – Influenza (Flu) – Influenza Vaccine Quadrivalent Inactivated high Dose	<ul style="list-style-type: none"> Updated to include off license use in pregnant HSCT, CAR T-cell therapy recipients and SOT candidates and recipients. 	September 30, 2024
Special Situations for Immunization – Immunization Recommendations for Specific Populations (Immunosuppressed and Chronic Health Conditions)	<ul style="list-style-type: none"> Addition of recommendations for childhood cancer survivors. 	September 30, 2024

Section	Updates	Date
Biological products – Respiratory Syncytial Virus (RSV) - Respiratory Syncytial Virus Vaccine	<ul style="list-style-type: none"> Abrysvo™ licensed in Canada on January 4, 2024. Introduced Respiratory Syncytial Virus (RSV) Vaccine into the routine immunization program for residents of continuing care homes and senior supportive living accommodations that are 60 years of age and older and community dwelling seniors 75 years of age. 	September 30, 2024
Introduction to AIP – Alberta Outreach Immunization Program	<ul style="list-style-type: none"> Addition of RSV vaccine to the outreach program. 	September 27, 2024
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include Pfizer BioNTech KP.2 COVID-19 vaccine storage and handling requirements. 	September 27, 2024
Biological products – Influenza (Flu) – Influenza Vaccine Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated product monograph and the influenza viral strains included in the vaccine. Added off-license use recommendations. 	September 24, 2024
Biological products – Influenza (Flu) – Influenza Vaccine High Dose Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated product monographs, the influenza viral strains included in the vaccine and added Flucelvax® Quad vaccine. 	September 24, 2024
Biological products – Polio – Polio Vaccine	<ul style="list-style-type: none"> World Health Organization link indicating where polio is circulating updated. 	September 24, 2024
Introduction to AIP – Immunization Goals and Objectives	<ul style="list-style-type: none"> Removal of pneumococcal polysaccharide vaccine as no longer available. 	September 24, 2024
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include Moderna Spikevax KP.2 COVID-19 vaccine storage and handling requirements. 	September 23, 2024
Biological Products – COVID-19 – Pfizer BioNTech	<ul style="list-style-type: none"> Biological page marked as “No longer available” as Pfizer-BioNTech XBB.1.5 vaccine no longer available in Alberta. 	August 31, 2024
Biological Products – COVID-19 – Moderna Spikevax	<ul style="list-style-type: none"> Biological page marked as “No longer available” as Moderna Spikevax XBB.1.5 vaccine no longer available in Alberta. 	August 31, 2024
Biological products – Varicella – Varicella Vaccine	<ul style="list-style-type: none"> Updated to clarify the two-dose eligibility for different age groups. 	August 31, 2024
Biological Products – Mpox – Smallpox and Mpox Vaccine	<ul style="list-style-type: none"> Updated to align with national recommendations in the context of an ongoing immunization program. 	August 20, 2024
Biological Products – Tdap – Policy for Pharmacists Providing Tdap vaccine	<ul style="list-style-type: none"> Updated to clarify that all pregnant individuals are eligible. 	August 1, 2024
Biological Products – Tdap: Tetanus-Diphtheria-Acellular Pertussis Combined Vaccine	<ul style="list-style-type: none"> Updated to clarify that all pregnant individuals are eligible. 	August 1, 2024
Biological products – COVID-19 – Novavax	<ul style="list-style-type: none"> Biological page marked as “No longer available” as product is not available in Alberta. 	August 1, 2024
Biological Products – Pneumococcal – Pneumococcal Vaccine, 20-valent Conjugate	<ul style="list-style-type: none"> To clarify that individuals 65 years of age and older who have not received Pneu-P on or after 65 years of age or a dose of Pneu-C20 at any age, are eligible for a dose of Pneu-C20 vaccine. 	July 24, 2024

AIP Table of Updates

Section	Updates	Date
Biological products – MMR-Var: Measles-Mumps-Rubella- Varicella Combined Vaccine	<ul style="list-style-type: none"> Updated the <i>Areas where measles is circulating in Canada</i> section. 	July 19, 2024
Biological products – MMR: Measles-Mumps-Rubella- Combined Vaccine	<ul style="list-style-type: none"> Updated the <i>Areas where measles is circulating in Canada</i> section. 	July 19, 2024
Biological Products Pneumococcal – Pneumococcal Vaccine, 13- valent Conjugate and Pneumococcal – Pneumococcal Vaccine, 23- valent Polysaccharide	<ul style="list-style-type: none"> Biological pages watermarked 'No Longer Available'. 	July 2, 2024
Policy for Pharmacists – Providing Pneumococcal Polysaccharide 23 Valent Vaccine, Pneumococcal Decision Tree for Pharmacists	<ul style="list-style-type: none"> Links removed as Pneumococcal Polysaccharide 23 valent vaccine no longer available as publicly funded vaccine. 	July 2, 2024
Biological Products – DTaP-IPV-Hib: Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus influenzae type b Conjugate, and DTaP-IPV-Hib-HB: Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus influenzae type b Conjugate- Hepatitis B	<ul style="list-style-type: none"> Updated to include Pentacel® product. 	July 2, 2024
Immunization schedules – Routine Childhood Immunization Schedule, Infants: Routine Schedule, School Immunization Schedule and Adult Immunization Schedule	<ul style="list-style-type: none"> To reflect eligibility and schedule for Pneumococcal 15-valent Conjugate vaccine (Vaxneuvance®) into routine program for children and replacing Prevnar® 13. To reflect eligibility and schedule for Pneumococcal 20-valent Conjugate vaccine (Prevnar 20™), replacing Pneumococcal Polysaccharide vaccine (Pneumovax® 23). 	July 2, 2024
History of Immunization in Alberta – Alberta Immunization Program Changes	<ul style="list-style-type: none"> End dates added for Pneumococcal 13-valent Conjugate vaccine (Prevnar® 13) and Pneumococcal Polysaccharide vaccine (Pneumovax® 23). Start dates added for Pneumococcal 15-valent Conjugate vaccine (Vaxneuvance®) and Pneumococcal 20-valent Conjugate vaccine (Prevnar 20™) 	July 2, 2024

AIP Table of Updates

Section	Updates	Date
Biological products Pneumococcal: Policy for Pharmacists Providing Pneumococcal Conjugate 20-Valent Vaccine	<ul style="list-style-type: none"> Switch from Pneumococcal Polysaccharide 23-valent vaccine (Pneumo-P) to Pneumococcal 20-valent Conjugate Vaccine (Pnevnar 20™) in pharmacies for individuals 18 years of age and older who are at an increased risk of developing invasive pneumococcal disease (IPD). 	July 1, 2024
Introduction to AIP – Alberta Outreach Immunization Program	<ul style="list-style-type: none"> Updated Alberta Outreach Immunization Program policy for Fall 2024. 	June 28, 2024, 2024
Special situations for immunization – Immunization Recommendations for Specific Populations (Immunocompromised and Chronic Health Conditions)	<ul style="list-style-type: none"> Updated to incorporate replacement of Pneu-C 13 and Pneumo-P with Pneu-C 20 (Pnevnar 20™). 	June 28, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients: Child HSCT, Adult HSCT, Child SOT (before 18 months of age), Child SOT (after 18 months of age), Adult SOT	<ul style="list-style-type: none"> Updated to incorporate replacement of Pneu-C 13 and Pneumo-P with Pneu-C 20 (Pnevnar 20™). 	June 24, 2024
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Moderna extended the time vaccine can be transported up to 36 hours. 	June 24, 2024
Introduction to AIP – Immunization Goals and Objectives	<ul style="list-style-type: none"> Note added to indicate that immunization coverage rates for measles, mumps, rubella, and varicella are re-assessed by age seven, thirteen, and seventeen to align with when immunization services are offered through the school immunization program. 	June 24, 2024
Biological Products – Pneumococcal – Pneumococcal Vaccine, 20-valent Conjugate	<ul style="list-style-type: none"> Pnevnar 20™ Pneumococcal Conjugate (20 valent) - Introduced into the routine immunization program for high-risk individuals 2 months of age and older who belong to one or more of the groups at increased risk for Invasive Pneumococcal Disease (IPD) and for all individuals 65 years and older who have not previously received a dose of Pneumo-P or Pneu-C20. 	June 24, 2024
Biological Products – Pneumococcal – Pneumococcal Vaccine, 15-valent Conjugate	<ul style="list-style-type: none"> Introduced into routine program for children replacing Pnevnaar® 13. 	June 24, 2024

AIP Table of Updates

Section	Updates	Date
<p>Introduction – Immunization Goals and Objectives, Roles and Responsibilities. General Principles – Occupational Immunization Considerations. History of Immunization in Alberta – Alberta Immunization Program Changes Immunization schedules Routine Childhood Immunization Schedule, Infants: Routine Schedule, School Immunization Schedule, and Adult Immunization Schedule Biological Products Tdap: Tetanus-Diphtheria-Acellular Pertussis Combined Vaccine, Policy for pharmacists providing pertussis (Tdap) vaccine for pregnant women, Tdap-IPV: Tetanus-Diphtheria- Acellular Pertussis-Polio Combined Vaccine. Polio: Polio Vaccine. Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child SOT (before 18 months of age) and Adult SOT</p>	<ul style="list-style-type: none"> References to dTap changed to Tdap to align with national standards. 	<p>May 6, 2024</p>
<p>Biological products – COVID-19 – Novavax</p>	<ul style="list-style-type: none"> Includes indications for an additional COVID-19 XBB.1.5 vaccine dose for eligible individuals. Decrease from two-dose series to single dose for unimmunized individuals who are not moderately to severely immunocompromised. Three-dose series for post-hematopoietic stem cell transplant (HSCT) and/or chimeric antigen receptor (CAR) T-cell therapy recipients. 	<p>April 15, 2024</p>
<p>Biological Products – COVID-19 – Pfizer BioNTech</p>	<ul style="list-style-type: none"> Includes indications for an additional COVID-19 XBB.1.5 vaccine dose for eligible individuals. Three-dose series for post-hematopoietic stem cell transplant (HSCT) and/or chimeric antigen receptor (CAR) T-cell therapy recipients. 	<p>April 15, 2024</p>
<p>Biological Products – COVID-19 – Moderna Spikevax</p>	<ul style="list-style-type: none"> Includes indications for an additional COVID-19 XBB.1.5 vaccine dose for eligible individuals. Three-dose series for post-hematopoietic stem cell transplant (HSCT) and/or chimeric antigen receptor (CAR) T-cell therapy recipients. 	<p>April 15, 2024</p>

AIP Table of Updates

Section	Updates	Date
General principles Assessment Expected Prior to Vaccine Administration	<ul style="list-style-type: none"> Updated antiviral section. 	April 12, 2024
Special situations for immunization Immunization Recommendations for Specific Populations (Immunosuppressed and Chronic Health Conditions)	<ul style="list-style-type: none"> Updated and expanded Congenital Immunodeficiency section. Updated HIV section to align with CIG wording and Alberta HIV infectious disease physician expert opinion. 	April 12, 2024
Special situations for immunization Principles of Immunization for HSCT and SOT Recipients	<ul style="list-style-type: none"> Updated to indicate the difference between the autologous and allogenic HSCT schedules. 	April 12, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Adult HSCT	<ul style="list-style-type: none"> Updated Shingrix® (herpes zoster vaccine) recommendation for autologous HSCT recipients. Consideration for early MMR vaccine post-transplant. 	April 12, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child HSCT	<ul style="list-style-type: none"> Consideration for early MMR vaccine post-transplant. 	April 12, 2024
Cold Chain Storage and Handling Alberta Vaccine Storage and Handling Policy for Provincially Funded Vaccine	<ul style="list-style-type: none"> Additional information provided for Pharmacy Wholesale Distributors reporting cold chain excursions. 	April 8, 2024
Biological products Varicella: Varicella Vaccine	<ul style="list-style-type: none"> Varilrix® product available in Alberta. 	April 8, 2024
Immunization schedules Infants: Routine Immunization Schedule and Routine Childhood Immunization Schedule	<ul style="list-style-type: none"> Updated to reflect that first dose of MMR-Var should be offered to children at 12 months and second dose at 18 months of age as of policy updates from January 2021. 	April 3, 2024
Biological products MMR-Var: Measles-Mumps-Rubella-Varicella Combined Vaccine	<ul style="list-style-type: none"> Updated to indicate that this vaccine is no longer routinely offered to children between 4 and 6 years of age as a catch-up, because all children in this age group will now have been offered vaccine at 18 months of age. Identified areas where measles is circulating in Canada. 	April 3, 2024
Biological products MMR: Measles-Mumps-Rubella-Combined Vaccine	<ul style="list-style-type: none"> Updated to indicate that children older than 18 months of age and younger than 4 years of age who have only received one dose of vaccine are no longer considered up-to-date for measles. Clarification on the locations where measles is circulating in Canada. Immunization is now recommended for all measles-susceptible individuals travelling to any country outside of Canada (including all of the U.S.). 	April 3, 2024

AIP Table of Updates

Section	Updates	Date
General principles Occupational Immunization Considerations	<ul style="list-style-type: none"> Addition to indicate that adults in health care settings should receive a primary series and a single lifetime reinforcing dose of polio vaccine. 	April 2, 2024
Biological products TIG Tetanus Immune Globulin	<ul style="list-style-type: none"> New product monograph and new manufacturing process. 	April 2, 2024
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	<ul style="list-style-type: none"> Post-immunization serology recommendations updated. 	April 2, 2024
Adverse Events - Immunization Adverse Events Following Immunization (AEFI) Policy for Alberta Immunization Providers	<ul style="list-style-type: none"> References updated. 	April 2, 2024
Immunization schedules School Immunization Schedule and Adult Immunization Schedule	<ul style="list-style-type: none"> Addition of recommendation for COVID-19 vaccines as per policy updates/changes from August 2022. 	January 29, 2024
Immunization schedules Infants: Routine Immunization Schedule and Routine Childhood Immunization Schedule	<ul style="list-style-type: none"> Addition of recommendations for COVID-19 vaccines as per policy updates from August 2022. DTaP-IPV-Hib-HB replacing DTaP-IPV-Hib as part of routine immunizations for 2,4,6 months of age. 	January 29, 2024
Biological products Polio Vaccine	<ul style="list-style-type: none"> Removed limited supply constraints. Adults in Health Care Settings should receive a primary series and a single lifetime reinforcing dose. Adults previously unimmunized with polio vaccine should receive a primary series. 	January 29, 2024
Biological products dTap-IPV: Diphtheria-Tetanus-Acellular Pertussis Polio-Combined Vaccine	<ul style="list-style-type: none"> Removed limited supply constraints related to IPV vaccine. Adults in Health Care Settings should receive a primary series and a single lifetime reinforcing dose of polio-containing vaccine. Adults previously unimmunized with polio vaccine should receive a primary series. 	January 29, 2024
Special situations for immunization Immunization Recommendations for Specific Populations (Immunosuppressed and Chronic Health Conditions)	<ul style="list-style-type: none"> Updated to include COVID-19 vaccine. Addition of CAR T-cell therapy to guidelines. Revised "Summary Table for Immunizations when on Biologics" (p. 10) 	January 29, 2024
Special situations for immunization Principles of Immunization for HSCT and SOT Recipients	<ul style="list-style-type: none"> Guidelines were reviewed by expert working group, updated for clarity and to incorporate wording and policy changes. 	January 29, 2024

AIP Table of Updates

Section	Updates	Date
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Adult HSCT	<ul style="list-style-type: none"> • Addition of Chimeric Antigen Receptor T (CAR T-cell therapy) to guidelines. • Expanded HPV eligibility for individuals up to 45 years of age. • Updated Shingrix® (herpes zoster vaccine) recommendation for autologous HSCT recipients. • Added information on RSV vaccine. • Additional information on travel vaccines included. 	January 29, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child HSCT	<ul style="list-style-type: none"> • Addition of Chimeric Antigen Receptor T (CAR T-cell therapy) to guidelines. • Additional information on travel vaccines included. 	January 29, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Adult SOT	<ul style="list-style-type: none"> • Serology for measles and rubella IgG post-immunization no longer recommended. • Expanded HPV eligibility for individuals up to 45 years of age. • Third dose VZ recommended for specific groups at request of transplant physician. • Added RSV vaccine (Arexvy®) information to non-routine vaccines. • Addition of information on travel vaccines. 	January 29, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child SOT (after 18 months of age)	<ul style="list-style-type: none"> • Serology recommendations for measles, rubella, and varicella updated. • Third dose VZ recommended for specific groups at request of transplant physician. • Addition of information on travel vaccines. 	January 29, 2024
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child SOT (before 18 months of age)	<ul style="list-style-type: none"> • Serology recommendations for measles, rubella, and varicella updated. • Addition of information on travel vaccines. 	January 29, 2024
Biological products Rotavirus: Rotavirus Vaccine	<ul style="list-style-type: none"> • Added link to <i>Summary Table for Immunizations when on Biologics</i> to highlight that infants whose mothers were taking biologics during pregnancy may be eligible to receive rotavirus vaccine. 	January 29, 2024
Biological products Varicella: Varicella Vaccine	<ul style="list-style-type: none"> • Third dose provincially funded for solid organ transplant candidates if VZ IgG after second dose at the request of the transplant physician. 	January 29, 2024
Biological products HPV: Human Papillomavirus Vaccine	<ul style="list-style-type: none"> • Expanded indications for provincially funded vaccine to include SOT and HSCT recipients up to 45 years of age. 	January 29, 2024
Biological products Herpes Zoster: Herpes Zoster – Shingrix Vaccine	<ul style="list-style-type: none"> • Expanded indications for provincially funded vaccine to include autologous HSCT recipients 18 years of age and older. 	January 29, 2024
Biological products – COVID-19 – Novavax	<ul style="list-style-type: none"> • Updated to include CAR T-cell therapy. 	January 29, 2024
Biological Products – COVID-19 – Pfizer BioNTech	<ul style="list-style-type: none"> • Updated to include CAR T-cell therapy. 	January 29, 2024

AIP Table of Updates

Section	Updates	Date
Biological Products – COVID-19 – Moderna Spikevax	<ul style="list-style-type: none"> Updated to include CAR T-cell therapy. 	January 29, 2024
History of Immunization in Alberta – Alberta Immunization Program Changes	<ul style="list-style-type: none"> Updated to incorporate Novavax XBB.1.5 vaccine. 	January 29, 2024
Biological products – COVID-19 – Novavax	<ul style="list-style-type: none"> December 05, 2023 – Licensed for use in Canada. January 05, 2024 – Implemented in Alberta. 	January 5, 2024
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include Novavax XBB.1.5 vaccine storage and handling requirements. 	December 14, 2023
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child HSCT, Adult HSCT, Child SOT (before 18 months of age), Child SOT (after 18 months of age), & Adult SOT	<ul style="list-style-type: none"> Updated COVID-19 vaccine schedule. 	December 5, 2023
Biological Products — Ebola Vaccine	<ul style="list-style-type: none"> Biological page created as product available for special order via SAP program. 	December 4, 2023
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Contact information for Moderna product cold chain excursions updated. 	December 4, 2023
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	<ul style="list-style-type: none"> Post-immunization serology recommendations updated. 	December 4, 2023
Biological Products – COVID-19 – Moderna Spikevax	<ul style="list-style-type: none"> Updated schedule for unimmunized individuals 5 years of age and older who are moderately to severely immunocompromised as per NACI recommendations. Removal of preferential statement recommending Pfizer-BioNTech for individuals 12 to 29 years of age, as per NACI recommendations. 	December 4, 2023
Biological Products – COVID-19 – Pfizer BioNTech	<ul style="list-style-type: none"> Updated schedule for unimmunized individuals 5 years of age and older who are moderately to severely immunocompromised as per NACI recommendations. Removal of preferential statement recommending Pfizer-BioNTech for individuals 12 to 29 years of age, as per NACI recommendations. 	December 4, 2023
Biological products Polio Vaccine	<ul style="list-style-type: none"> Updated to clarify where polio is circulating. 	October 10, 2023
Biological Products – COVID-19 – Pfizer BioNTech	<ul style="list-style-type: none"> September 28, 2022 – Licensed for use in Canada. October 16, 2023 – Implemented in Alberta. 	October 10, 2023

AIP Table of Updates

Section	Updates	Date
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Principles of Immunization in HSCT and SOT Recipients, Child HSCT, Adult HSCT, Child SOT (before 18 months of age), Child SOT (after 18 months of age), & Adult SOT	<ul style="list-style-type: none"> Updated to include the XBB.1.5 COVID-19 vaccine formulation. 	October 10, 2023
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include Pfizer XBB.1.5 vaccine storage and handling requirements. 	October 6, 2023
COVID-19 resources for health care practitioners Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated to incorporate Moderna XBB.1.5 vaccine. 	October 2, 2023
History of Immunization in Alberta – Alberta Immunization Program Changes	<ul style="list-style-type: none"> Updated to incorporate Moderna XBB.1.5 vaccine. Pfizer BioNTech Comirnaty and Moderna Spikevax bivalent (Original and Omicron) vaccines end dated. Updated to include Novavax end date of June 30, 2023. 	October 2, 2023
Biological Products – COVID-19 – Moderna Spikevax	<ul style="list-style-type: none"> September 12, 2023 – Licensed for use in Canada. October 3, 2023 – Implemented in Alberta. 	September 27, 2023
COVID-19 resources for health care practitioners World Health Organization Approved vaccines	<ul style="list-style-type: none"> Updated to accommodate Moderna XBB.1.5 vaccine. 	September 27, 2023
General principles Occupational Immunization Considerations	<ul style="list-style-type: none"> Updated to clarify that current practice is not to assess and immunize all health care workers, including lab workers, for polio immunization due to the generally low risk of exposure to polio in Alberta and Canada, availability of PPE and the limited supply of vaccine. 	September 25, 2023
Biological products Polio Vaccine	<ul style="list-style-type: none"> Updated to offer a primary series and reinforcing dose to wastewater workers who handle sewage at wastewater treatment plants. Updated to indicate that adults receiving polio vaccine for the purpose of travel or health care students receiving it prior to placement are not eligible for provincially funded vaccine and must purchase vaccine through a local travel health professional. Updated to clarify that current practice is not to assess and immunize all health care workers, including lab workers, for polio immunization due to the generally low risk of exposure to polio in Alberta and Canada, availability of PPE and the limited supply of vaccine. 	September 25, 2023

AIP Table of Updates

Section	Updates	Date
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include Moderna XBB.1.5 vaccine storage and handling requirements. 	September 15, 2023
Biological products Varicella: Varicella Vaccine	<ul style="list-style-type: none"> Varilrix® product not currently available in Alberta. Expert advice allowing off-license use of VARIVAX® III in children with acute lymphocytic leukemia (ALL) and persons receiving other immunosuppressive treatment. 	September 1, 2023
Adverse Events - Immunization Adverse Events Following Immunization (AEFI) Policy for Alberta Immunization Providers	<ul style="list-style-type: none"> Updated the anaphylaxis criteria section 	August 21, 2023
Biological products Meningococcal: Meningococcal Conjugate (Groups A,C,Y and W-135) Vaccine	<ul style="list-style-type: none"> Updated to clarify that immunization for outbreak control may continue beyond the closure of an outbreak when recommended by the Chief Medical Officer of Health. 	August 16, 2023
History of immunization in Alberta Alberta Immunization Program Changes	<ul style="list-style-type: none"> End dates added to original (monovalent) COVID-19 products that are no longer available for use in Alberta. Added start date of Moderna BA.4/5 bivalent vaccine. 	August 2, 2023
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child HSCT, Adult HSCT, Child SOT (after 18 months of age), & Adult SOT	<ul style="list-style-type: none"> Updated to refer to Alberta Health’s biological product pages for COVID-19 booster dose information. 	August 2, 2023
Special situations for immunization – Immunization recommendations for transplant candidates and recipients Child SOT (before 18 months of age)	<ul style="list-style-type: none"> Updated to refer to the rotavirus biological page if a first dose is inadvertently given after 15 weeks of age. 	August 2, 2023
Biological products Influenza: Influenza Vaccine Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated for 2023/2024 Influenza season. 	August 2, 2023
Biological products Influenza: Influenza Vaccine High Dose Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated for 2023/2024 Influenza season. 	August 2, 2023
Cold Chain Storage and Handling – Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Original monovalent mRNA products removed. Moderna bivalent original and omicron BA.4/5 vaccine added. 	August 2, 2023

AIP Table of Updates

Section	Updates	Date
Biological Products – COVID-19 – Pfizer-BioNTech (Original & Omicron BA.4/5) 5 Years +	<ul style="list-style-type: none"> Biological pages for the Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) vaccine for 5 to 11 years, and for 12 years of age and older, are combined. These vaccines are now recommended for use as a COVID-19 vaccine primary series. 	August 2, 2023
Biological Products – COVID-19 – Moderna Spikevax (Original & Omicron BA.4/5) 6 Months+	<ul style="list-style-type: none"> New biological page. Product for use as a COVID-19 primary series for all children 6 months of age to 4 years. May also be used as a COVID-19 primary series for individuals 5 years of age and older who are moderately to severely immunocompromised. 	August 2, 2023
Biological Products – COVID-19 resources for health practitioners – Guidance on World Health Organization Approved COVID-19 Vaccines	<ul style="list-style-type: none"> This new document contains guidance for individuals who received World Health Organization approved vaccines. The information was previously contained in two different policies: Vaccine Eligibility and Scheduling & Defining a COVID-19 Vaccine Primary Series. 	August 2, 2023
Biological Products – COVID-19 resources for health practitioners – Defining a COVID-19 Vaccine Primary Series	<ul style="list-style-type: none"> Archived due to reduced number of COVID-19 vaccine options. 	August 2, 2023
Biological Products – COVID-19 resources for health practitioners – Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Archived due to reduced number of COVID-19 vaccine options. 	August 2, 2023
Biological Products – COVID-19 resources for health practitioners – Allergy Pathways	<ul style="list-style-type: none"> Removed reference to purple cap Pfizer-BioNTech product. 	August 2, 2023
Biological Products Moderna Spikevax Original 6 months to 5 years	<ul style="list-style-type: none"> Archived now that bivalent products are in use for a primary series. 	August 2, 2023
Biological Products Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) 5 to 11 years	<ul style="list-style-type: none"> Archived now that bivalent products are in use for a primary series. 	August 2, 2023
Biological Products Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) 12+ years	<ul style="list-style-type: none"> Archived now that bivalent products are in use for a primary series. 	August 2, 2023
Biological Products Pfizer-BioNTech Original 6 months to 4 years	<ul style="list-style-type: none"> Archived now that bivalent products are in use for a primary series. 	August 2, 2023
Biological Products Pfizer-BioNTech Original 5 to 11 years	<ul style="list-style-type: none"> Archived now that bivalent products are in use for a primary series. 	August 2, 2023
Biological Products Pfizer-BioNTech Original 12+ years	<ul style="list-style-type: none"> Archived now that bivalent products are in use for a primary series. 	August 2, 2023

AIP Table of Updates

Section	Updates	Date
Special situations for immunization Immunization Recommendations for Specific Populations (Immunosuppressed and Chronic Health Conditions)	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Hepatitis B (HBVD) Algorithm for Chronic Renal Disease	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Principles of Immunization for HSCT and SOT Recipients	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Immunization for Child HSCT	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Immunization for Child SOT (Before 18 Months of Age)	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Immunization for Child SOT (After 18 Months of Age)	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Special situations for immunization Immunization for Adult SOT Candidates and Recipients	<ul style="list-style-type: none"> Updated to clarify the scope/purpose of the document. No clinical changes. 	July 18, 2023
Introduction Alberta Outreach Immunization Program	<ul style="list-style-type: none"> New Alberta Outreach Immunization Program policy. 	July 4, 2023
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Product no longer available in Canada. Biological page archived. 	June 30, 2023
Biological products Influenza (Flu) – Influenza Immunization Policy	<ul style="list-style-type: none"> Policy removed and archived. 	June 30, 2023
Biological products Mpox: Smallpox and Mpox Vaccine	<ul style="list-style-type: none"> Storage and handling section updated as per product monograph updates from March 10, 2023, and correspondence from the Public Health Agency of Canada. 	June 30, 2023
Alberta Immunization Policy COVID-19 documents Alberta COVID-19 Immunization Policy	<ul style="list-style-type: none"> Policy removed and archived. 	June 30, 2023

AIP Table of Updates

Section	Updates	Date
COVID-19 and Immunization Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Removed storage and handling information for Moderna Spikevax 6 to 11 years, 12 years of age and older, and BA.1/BA.2 bivalent vaccine as no longer offering products in Alberta. Removal of storage and handling information for Janssen COVID-19 vaccine as no longer available in Alberta. 	June 30, 2023
Biological products Diphtheria Antitoxin (equine)	<ul style="list-style-type: none"> Updated to include information about storage and returning product that is unused. 	June 30, 2023
Biological products Botulism Antitoxin Heptavalent Types A to G	<ul style="list-style-type: none"> Updated to include information about returning product that is unused. 	June 30, 2023
History of Immunizations in Alberta History of Biological Administration in Alberta	<ul style="list-style-type: none"> Document removed and archived. 	April 25, 2023
Biological products Diphtheria Antitoxin (equine)	<ul style="list-style-type: none"> Butantan Institute product added. 	April 25, 2023
Biological products Td: Diphtheria-Tetanus Combined Vaccine	<ul style="list-style-type: none"> Archived biological page as no longer offering product in Alberta. 	April 21, 2023
Biological products COVID-19 Vaccine – AstraZeneca/COVISHIELD vaccine	<ul style="list-style-type: none"> Archived biological page as no longer offering product in Alberta. 	April 21, 2023
Biological Products Moderna Spikevax Original (Non-Bivalent) 12+ years	<ul style="list-style-type: none"> Archived biological page as no longer offering product in Alberta. 	April 21, 2023
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine 6-11 years	<ul style="list-style-type: none"> Archived biological page as no longer offering product in Alberta. 	April 21, 2023
Biological Products Moderna Spikevax Omicron-Containing Bivalent (Original and Omicron BA.1) 18+ years	<ul style="list-style-type: none"> Archived biological page as no longer offering product in Alberta. 	April 21, 2023
Immunization and COVID-19 Covid-19 Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Updated to reflect that the Moderna Spikevax Omicron-containing Bivalent (Original and Omicron BA.1) and Moderna Spikevax 0.20mg/mL formulation are no longer available in Alberta. 	April 21, 2023
Biological Products Pfizer-BioNTech Original (Non-Bivalent) 12+ years	<ul style="list-style-type: none"> Removed references to Moderna Spikevax Original for primary series as vaccine is no longer available in Alberta. 	April 21, 2023
Biological Products Pfizer-BioNTech Original 5 to 11 years	<ul style="list-style-type: none"> Removed references to Moderna Spikevax Original for primary series as vaccine is no longer available in Alberta. 	April 21, 2023

AIP Table of Updates

Section	Updates	Date
Biological Products Moderna Spikevax Original (Non-Bivalent) 6 months to 5 years	<ul style="list-style-type: none"> Updated indications section to reflect unavailability of Moderna Original vaccine products for children 6 years of age and older. 	April 21, 2023
COVID-19 and Immunization Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Removal of the Moderna Spikevax Omicron-containing Bivalent (Original and Omicron BA.1) and Moderna Spikevax 0.20mg/mL formulation information as products no longer available in Alberta. 	April 21, 2023
Biological Products Pfizer-BioNTech Original 5 to 11 years	<ul style="list-style-type: none"> Updated information related to myocarditis and pericarditis as per updated product monograph. 	March 31, 2023
COVID-19 and Immunization Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated to indicate that Sinovac vaccine is valid for children 3 to 17 years of age. 	March 31, 2023
Introduction to AIP Immunization Goals and Objectives	<ul style="list-style-type: none"> Updated to clarify the age cohort for vaccines routinely offered in grade 6 and grade 9. 	March 24, 2023
COVID-19 and Immunization Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include expanded shelf-life from 6 hours to 12 hours post-puncture for Novavax. 	March 24, 2023
Immunization and COVID-19 Covid-19 Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Updated to reflect booster dose recommendations. 	March 24, 2023
Alberta Immunization Policy COVID-19 documents Alberta COVID-19 Immunization Policy	<ul style="list-style-type: none"> Updated to include revised booster dose recommendations. Updated PINS table for pharmacy use. 	March 24, 2023
Special situations for immunization Immunization for Child HSCT	<ul style="list-style-type: none"> Updated to include COVID-19 vaccine primary series for 6 months to 4 years of age. Updated to include revised COVID-19 booster dose recommendations. 	March 20, 2023
Special situations for immunization Immunization for Adult SOT Candidates and Recipients	<ul style="list-style-type: none"> Updated to include revised COVID-19 booster dose recommendations. 	March 20, 2023
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Updated to include revised COVID-19 booster dose recommendations. 	March 20, 2023
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Updated bivalent booster spacing considerations to 6 months after last dose or infection. 	March 20, 2023
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Updated booster spacing considerations to 6 months after last dose or infection. 	March 20, 2023

AIP Table of Updates

Section	Updates	Date
Biological Products Moderna Spikevax Omicron-Containing Bivalent (Original and Omicron BA.1) 18+ years	<ul style="list-style-type: none"> Updated to include additional bivalent booster dose indications for eligible individuals and updated booster spacing considerations to 6 months between last dose or infection. 	March 20, 2023
Biological Products Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) 5 to 11 years	<ul style="list-style-type: none"> Updated booster spacing considerations to 6 months after last dose or infection. 	March 20, 2023
Biological Products Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) 12+ years	<ul style="list-style-type: none"> Updated to include additional bivalent booster dose indications for eligible individuals and updated booster spacing considerations to 6 months between last dose or infection. 	March 20, 2023
Biological Products Moderna Spikevax Original (Non-Bivalent) 6 to 11 years	<ul style="list-style-type: none"> Updated recommendations on timing of tuberculin skin testing/interferon gamma release assay and COVID-19 immunization. 	March 20, 2023
Biological products Mpox: Smallpox and Mpox Vaccine	<ul style="list-style-type: none"> Updated to expand pre-exposure eligibility for high-risk occupational exposure (laboratory research settings). 	March 1, 2023
Biological products Pneumococcal: Pneumococcal Vaccine, 23-valent Polysaccharide	<ul style="list-style-type: none"> Updated precautions to include co-administration of Shingrix vaccine. 	March 1, 2023
Biological products Herpes Zoster: Herpes Zoster – Shingrix Vaccine	<ul style="list-style-type: none"> Updated to include reports of fever and shivering when co-administered with Pneumococcal 23-valent Polysaccharide (PPV23) Vaccine 	March 1, 2023
Immunization and COVID-19 Covid-19 Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Updated to reflect booster dose recommendations. 	March 1, 2023
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological Products Moderna Spikevax Omicron-Containing Bivalent (Original and Omicron BA.1) 18+ years	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological Products Moderna Spikevax Original (Non-Bivalent) 6 months to 5 years	<ul style="list-style-type: none"> Updated language to align with other COVID-19 vaccine biological pages. 	March 1, 2023
Biological Products Moderna Spikevax Original (Non-Bivalent) 6 to 11 years	<ul style="list-style-type: none"> Removed the following sections: Appearance, Storage and Handling, Packaging, Non-Medicinal Ingredients, and Preparation/Reconstitution. 	March 1, 2023

AIP Table of Updates

Section	Updates	Date
Biological Products Moderna Spikevax Original (Non-Bivalent) 12+ years	<ul style="list-style-type: none"> Licensed use updated as per January 12, 2023, product monograph – booster dose licensed for 12 to 17 years of age. Updated booster dose recommendations. 	March 1, 2023
Biological Products Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) 12+ years	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological Products Pfizer-BioNTech Bivalent (Original and Omicron BA.4/BA.5) 5 to 11 years	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological Products Pfizer-BioNTech Original (Non-Bivalent) 6 months to 4 years	<ul style="list-style-type: none"> Updated language to align with other COVID-19 vaccine biological pages. 	March 1, 2023
Biological Products Pfizer-BioNTech Original (Non-Bivalent) 5 to 11 years	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological Products Pfizer-BioNTech Original (Non-Bivalent) 12+ years	<ul style="list-style-type: none"> Updated booster dose recommendations. 	March 1, 2023
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Removed the following sections: Possible Reactions, Appearance, Storage and Handling, Packaging, Non-Medicinal Ingredients and Preparation/Reconstitution. Updated booster dose recommendations. 	January 20, 2023
Alberta Immunization Policy COVID-19 documents Alberta COVID-19 Immunization Policy	<ul style="list-style-type: none"> Addition of bivalent booster dose for children 5 to 11 years of age. 	January 20, 2023
Immunization and COVID-19 Defining a COVID-19 Vaccine Primary Series	<ul style="list-style-type: none"> Updated to include Pfizer-BioNTech primary series for children 6 months to 4 years of age and Moderna primary series for children 6 months to 5 years of age. 	January 20, 2023
Immunization and COVID-19 Covid-19 Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Addition of Pfizer BioNTech BA.4/BA.5 bivalent booster dose for children 5 to 11 years of age. Expanded Novavax eligibility for children 12 to 17 years of age. 	January 20, 2023
Biological products Pfizer-BioNTech Bivalent Original and Omicron BA.4/BA.5 (5 to 11 years)	<ul style="list-style-type: none"> December 09, 2022 – Licensed for use in Canada January 05, 2023 – Implemented in Alberta 	January 5, 2023
Biological products Pfizer-BioNTech Monovalent (5 to 11 years)	<ul style="list-style-type: none"> Updated booster dose indications to align with January 5, 2022, implementation of Pfizer BioNTech Bivalent COVID-19 vaccine (Original & Omicron BA.4/BA.5) vaccine for children 5 to 11 years of age. 	January 5, 2023

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Updated to include licensed use as a primary series for children 12 to 17 years of age, and to include off-license use of Novavax as a booster dose in children 12 to 17 years of age. 	January 5, 2023
Biological Products Pfizer-BioNTech Monovalent (6 months to 4 years)	<ul style="list-style-type: none"> Updated to include new co-administration recommendations. 	December 22, 2022
Biological Products Moderna Monovalent (6 months to 5 years)	<ul style="list-style-type: none"> Updated to include new co-administration recommendations. 	December 22, 2022
COVID-19 and Immunization Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Addition of Pfizer-BioNTech Bivalent 5-11y vaccine. 	December 19, 2022
Biological Products Mpox: Smallpox Antiviral (TPOXX)	<ul style="list-style-type: none"> Updated to expand eligibility. Updated to clarify access and authorization. 	December 09, 2022
Biological products Mpox: Smallpox and Mpox Vaccine	<ul style="list-style-type: none"> Updated with revised disease name (mpox) from the World Health Organization. Updated co-administration recommendation. Updated to clarify that pre-exposure use in individuals less than 18 years of age is off-license. 	December 09, 2022
Biological products Pneumococcal: Pneumococcal Vaccine, 23-valent Polysaccharide	<ul style="list-style-type: none"> Updated recommendation for adults who privately purchase 20-valent pneumococcal conjugate vaccine. 	December 09, 2022
Biological products MMR-Var: Measles-Mumps-Rubella-Varicella Combined Vaccine	<ul style="list-style-type: none"> Updated to indicate that Priorix-Tetra is not currently available. 	December 01, 2022
Biological products Pfizer-BioNTech Monovalent 12+	<ul style="list-style-type: none"> Updated to remove purple cap formulation as this product is no longer available. 	December 01, 2022
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Licensed use updated as per November 17, 2022, product monograph – booster dose licensed for 18 years of age and older. 	December 01, 2022
Biological products Moderna Monovalent (12+)	<ul style="list-style-type: none"> Updated booster recommendations. 	December 01, 2022
COVID-19 and Immunization Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to remove Pfizer-BioNTech Monovalent 12+ purple cap formulation as no longer available. Onward transportation sections for Pfizer-BioNTech and Moderna products updated. 	December 01, 2022
COVID-19 and Immunization Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated with guidance for bivalent vaccines and monovalent vaccines for ages 6 months to 5 years. 	December 01, 2022
Alberta Immunization Policy COVID-19 documents Alberta COVID-19 Immunization Policy	<ul style="list-style-type: none"> Updated to include Pfizer-BioNTech vaccine for ages 6 months to 4 years. Updated booster dose recommendations. Updated PINS for pharmacy use. 	December 01, 2022

AIP Table of Updates

Section	Updates	Date
Immunization and COVID-19 Covid-19 Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Updated to incorporate Moderna 6 months to 5 years of age, Pfizer 6 months to 4 years of age and recent booster dose recommendations. 	December 01, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna (6 months – 5 years)	<ul style="list-style-type: none"> Updated to include preferential recommendation for Moderna Monovalent mRNA vaccine over Pfizer Monovalent mRNA vaccine for children 6 months to 4 years of age who are moderately to severely immunocompromised. Updated recommendations on timing of tuberculin skin testing/interferon gamma release assay and COVID-19 immunization. Removed the following sections: Possible Reactions, Appearance, Storage and Handling, Non-Medicinal Ingredients and Preparation/Reconstitution. 	November 14, 2022
Biological products COVID-19 Vaccine (mRNA) Pfizer Children 6 months to 4 years of age.	<ul style="list-style-type: none"> Implemented in Alberta. 	November 14, 2022
Biological products Botulism: Botulism Antitoxin Heptavalent Types A to G	<ul style="list-style-type: none"> Updated to include infant indication. 	October 26, 2022
Biological products Baby Botulism Immune Globulin- BabyBIG®	<ul style="list-style-type: none"> Product use discontinued in Alberta. 	October 26, 2022
Biological products Covid-19 Vaccine (mRNA) Pfizer Bivalent (Original and Omicron BA.4/BA.5) Vaccine	<ul style="list-style-type: none"> Implemented in Alberta. 	October 24, 2022
Biological products COVID-19 Vaccine (mRNA) Moderna Bivalent (Original and Omicron BA.1) Vaccine	<ul style="list-style-type: none"> Updated booster dose recommendation. Updated to align pregnancy and breastfeeding recommendations. 	October 24, 2022
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Updated booster dose recommendations Updated recommendations on timing of tuberculin skin testing/interferon gamma release assay and COVID-19 immunization. Removed the following sections: Additional Doses for Travel Purposes Only, Possible Reactions, Appearance, Storage and Handling, Packaging, Non-Medicinal Ingredients and Preparation/Reconstitution. 	October 24, 2022

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated booster recommendations. Updated recommendations on timing of tuberculin skin testing/interferon gamma release assay and COVID-19 immunization. Updated pregnancy and breastfeeding recommendations. Removed the following sections: Additional doses for travel purposes only, Possible Reactions, Appearance, Storage and Handling, Packaging, Non-Medicinal Ingredients and Preparation/Reconstitution. 	October 24, 2022
Biological products COVID-19 Vaccine (mRNA) Moderna frozen vaccine	<ul style="list-style-type: none"> Updated booster recommendations Updated recommendations on timing of tuberculin skin testing/interferon gamma release assay and COVID-19 immunization. Updated pregnancy and breastfeeding recommendations. Removed the following sections: Additional doses for travel purposes only, Possible Reactions, Appearance, Storage and Handling, Packaging, Non-Medicinal Ingredients and Preparation/Reconstitution. 	October 24, 2022
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to incorporate Pfizer Bivalent (Original and Omicron BA.4/BA.5) 	October 18, 2022
Biological products Monkeypox: Smallpox and Monkeypox Vaccine	<ul style="list-style-type: none"> Updated to expand eligibility for pre-exposure vaccination and roll out second doses for pre-exposure vaccination. 	October 11, 2022
Special situations for immunization Immunization of Adult SOT Candidates and Recipients	<ul style="list-style-type: none"> Updated to include 8 week spacing between varicella vaccine series and Shingrix® 	October 11, 2022
Biological products Tuberculin PPD	<ul style="list-style-type: none"> Updated to clarify TST eligibility, including addition of uveitis, staff and volunteers at shelters and drop-in centres, and removal of the specific stages of chronic kidney disease. 	October 7, 2022
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Addition of Pfizer 6 Months to 4 Years (Maroon Cap) product. 	September 29, 2022
Alberta Immunization Policy COVID-19 documents Alberta COVID-19 Immunization Policy	<ul style="list-style-type: none"> Updated to include Moderna COVID-19 Bivalent Vaccine (Original and Omicron BA.1) 	September 29, 2022
Biological products COVID-19 Vaccine (mRNA) Moderna frozen vaccine	<ul style="list-style-type: none"> Removed use of Moderna (Royal Blue Cap) as adult booster. 	September 21, 2022
Biological products Monkeypox: Smallpox and Monkeypox Vaccine	<ul style="list-style-type: none"> Updated to include information about immunity following infection. 	September 21, 2022

AIP Table of Updates

Section	Updates	Date
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to incorporate Moderna Bivalent (Original and Omicron BA.1) vaccine 	September 21, 2022
Biological products COVID-19 Vaccine (mRNA) Moderna Bivalent (Original and Omicron BA.1) Vaccine	<ul style="list-style-type: none"> September 1, 2022 – Licensed for use in Canada September 21, 2022 – Implemented in Alberta 	September 21, 2022
Immunization and COVID-19 Covid-19 Vaccine Eligibility and Scheduling	<ul style="list-style-type: none"> Updated to incorporate Moderna Bivalent (Original and Omicron BA.1) vaccine 	September 15, 2022
Biological products COVID-19 Vaccine (mRNA) Pfizer Pediatric 5 to 11 years vaccine	<ul style="list-style-type: none"> Updated to implement first booster dose. 	August 31, 2022
Immunization and COVID-19 COVID-19 Immunization: Allergy Pathways - COVID-19 Immunization for Individuals with Allergies and Other Health Conditions	<ul style="list-style-type: none"> Updated to indicate that for a confirmed Tromethamine allergy, offer Purple Cap Pfizer (dilution required) formulation (if 12 years of age or older) or Novavax (if 18 years of age or older). 	August 10, 2022
Biological Products Monkeypox: Smallpox and Monkeypox Vaccine	<ul style="list-style-type: none"> Updated storage and handling section to ensure most recent information is available. 	August 10, 2022
Vaccine Storage and Handling Management Alberta Vaccine Storage and Handling Policy for Provincially Funded Vaccine	<ul style="list-style-type: none"> Updated to identify appropriate cold chain reporting process for community providers who receive vaccine from Accuristix. 	August 10, 2022
Alberta Immunization Policy COVID-19 documents Alberta COVID-19 Immunization Policy	<ul style="list-style-type: none"> Updated to include Moderna for children 6 months to 5 years of age. Updated immunization event reporting to 'as soon as possible' and required within 7 days. Redundant education resources removed. 	August 10, 2022
Biological products dTap: Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine	<ul style="list-style-type: none"> Updated to clarify indications for health care workers and health care students. 	August 10, 2022
Immunization goals and rates for Alberta Immunization Goals and Objectives	<ul style="list-style-type: none"> Updated rotavirus goal to a complete primary series rather than 3 doses, to include the Rotarix® 2 dose schedule. 	August 10, 2022
Biological products Meningococcal: Meningococcal Conjugate (Groups A,C,Y and W-135) Vaccine	<ul style="list-style-type: none"> Outbreak control added to Schedule section. 	August 10, 2022
Immunization schedules Infants: Routine Immunization Schedule	<ul style="list-style-type: none"> Third dose of rotavirus vaccine removed from the schedule because all remaining RotaTeq product expires July 29, 2022. 	July 29, 2022
Biological products Rotavirus: Rotavirus Vaccine	<ul style="list-style-type: none"> Updated to note that the RotaTeq product is not currently available in Alberta. 	July 29, 2022

AIP Table of Updates

Section	Updates	Date
Influenza immunization Influenza Immunization Policy	<ul style="list-style-type: none"> Revised policy for 2022-2023 influenza season. 	July 29, 2022
Imm/ARI data submission guidelines Reason codes by immunization phases for COVID-19 vaccine	<ul style="list-style-type: none"> Updated to include Moderna vaccine (6m-5yr). 	July 29, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna (6 months – 5 years)	<ul style="list-style-type: none"> July 14, 2022 – licensed for use in Canada August 2, 2022 – implemented in Alberta 	July 29, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to include potential use of Moderna (Royal Blue Cap) 0.1mg/mL formulation for 50 mcg adult booster doses to reduce wastage. 	July 29, 2022
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include COVID-19 Vaccine (mRNA) Moderna vaccine (6 months – 5 years) 	July 29, 2022
Biological Products Monkeypox: Smallpox and Monkeypox Vaccine	<ul style="list-style-type: none"> Updated to include indications for pre-exposure use. 	July 27, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine 6-11 years	<ul style="list-style-type: none"> Updated recommendations for timing of COVID-19 vaccines and receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prophylaxis of COVID-19. 	July 19, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Updated recommendations for timing of COVID-19 vaccines and receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prophylaxis of COVID-19. 	July 19, 2022
Adverse Events - Immunization Adverse Events Following Immunization (AEFI) Policy for Alberta Immunization Providers	<ul style="list-style-type: none"> Updated the anaphylaxis definition - Removed lip swelling out of the respiratory (upper airway swelling) criteria and move it into the dermatologic (angioedema) criteria section. 	July 19, 2022
Immunization and COVID-19 COVID-19 Immunization: Defining a COVID-19 Vaccine Primary Series	<ul style="list-style-type: none"> Defining Fully Immunized document converted to Defining a COVID-19 Vaccine Primary Series and to include recommendation for Albertans to receive all doses for which they are eligible. 	July 19, 2022
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include new product formulation (Gray Cap) that does not require dilution. 	July 19, 2022
Pfizer BioNTech COVID-19 Vaccine Adult and Pediatric Comparison Table	<ul style="list-style-type: none"> Updated to include new product formulation (Gray Cap) that does not require dilution. 	July 19, 2022
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Updated recommendations for timing of COVID-19 vaccines and receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prophylaxis of COVID-19. 	July 19, 2022

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Updated to expand second booster dose eligibility to include all individuals 18 years of age and older. Updated recommendations for timing of COVID-19 vaccines and receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prophylaxis of COVID-19. 	July 19, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to expand second booster dose eligibility to include all individuals 18 years of age and older. Updated recommendations for timing of COVID-19 vaccines and receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prophylaxis of COVID-19. 	July 19, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to expand second booster dose eligibility to include all individuals 18 years of age and older. Updated recommendations for timing of COVID-19 vaccines and receipt of anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma for treatment or prophylaxis of COVID-19. Updated to include new product formulation (Gray Cap) that does not require dilution. 	July 19, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> Addition of a single booster for Janssen vaccine. Updated information for individuals who received a partial primary series of WHO approved (non Health Canada approved). 	July 11, 2022
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Addition of a single booster dose. Updated possible reactions, and storage and handling to align with most recent product monograph. 	July 11, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine 6-11 years	<ul style="list-style-type: none"> Updated to lift restriction on co-administration with other vaccines. Removed reference to rescinded orders 02-2022 and 04-2022. 	July 11, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Updated to lift restriction on co-administration with other vaccines. Removed reference to rescinded orders 02-2022 and 04-2022. 	July 11, 2022
Biological products Tuberculin PPD	<ul style="list-style-type: none"> Updated to align with the Canadian Standards (8th edition). 	July 5, 2022
Adverse Events - Immunization Adverse Events Following Immunization (AEFI) Policy for Alberta Immunization Providers	<ul style="list-style-type: none"> Updated to reflect the replacement of Td product with dTap. 	June 30, 2022
Immunization schedules Routine Childhood Immunization Schedule	<ul style="list-style-type: none"> Updated to reflect the replacement of Td product with dTap. 	June 30, 2022
Immunization schedules Adult Immunization Schedule	<ul style="list-style-type: none"> Updated to reflect the replacement of Td product with dTap. 	June 30, 2022

AIP Table of Updates

Section	Updates	Date
Biological Products DTaP-IPV-Hib: Diphtheria-Tetanus-Acellular Pertussis-Polio-Haemophilus influenzae type b Conjugate	<ul style="list-style-type: none"> Updated to reflect the replacement of Td product with dTap. 	June 30, 2022
Biological products dTap: Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine	<ul style="list-style-type: none"> Updated to reflect the replacement of Td product with dTap. 	June 30, 2022
Biological products Td: Diphtheria-Tetanus Combined Vaccine	<ul style="list-style-type: none"> Remaining product expires in Alberta June 30, 2022 Biological page watermarked 'No Longer Available' 	June 30, 2022
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Addition of WHO approved CONVIDECIA COVID-19 vaccine. 	June 16, 2022
Immunization and COVID-19 COVID-19 Immunization: Defining Fully Immunized – COVID-19	<ul style="list-style-type: none"> Addition of WHO approved CONVIDECIA COVID-19 vaccine. 	June 16, 2022
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include extended storage time for Janssen COVID-19 vaccine in refrigerated state. 	June 16, 2022
Biological Products Monkeypox: Smallpox and Monkeypox Vaccine	<ul style="list-style-type: none"> New biological page for Smallpox and Monkeypox Vaccine. 	June 7, 2022
Biological Products Monkeypox: Smallpox Antiviral (TPOXX)	<ul style="list-style-type: none"> New biological page for Smallpox Antiviral, for off-license use in treatment of monkeypox. 	June 7, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> Updated to include a fifth dose for immunocompromised individuals eligible for a second booster. 	June 3, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra-frozen vaccine	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy and extended storage time in an ultra-frozen state. Updated to indicate that a second booster dose will correspond to a fifth dose for certain immunocompromised individuals. 	June 1, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy and extended storage time in an ultra-frozen state. 	June 1, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy. Updated to indicate that a second booster dose will correspond to a fifth dose for certain immunocompromised individuals. 	June 1, 2022

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine 6-11 years	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy. 	June 1, 2022
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy. Updated to indicate that a second booster dose will correspond to a fifth dose for certain immunocompromised individuals. 	June 1, 2022
Special situations for immunization Principles of Immunization in HSCT and SOT Recipients	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy. 	June 1, 2022
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy. Updated to allow COVID-19 and inactivated influenza vaccine to be administered as early as 3 months after HSCT at the discretion of the transplant physician. 	June 1, 2022
Special situations for immunization Immunization for Child HSCT	<ul style="list-style-type: none"> Updated to include recommendation for immunization post CAR-T cell therapy. Updated to allow COVID-19 and inactivated influenza vaccine to be administered as early as 3 months after HSCT at the discretion of the transplant physician. 	June 1, 2022
Pfizer BioNTech COVID-19 Vaccine Adult and Pediatric Comparison Table	<ul style="list-style-type: none"> Updated to include extended storage time in an ultra-frozen state. 	June 1, 2022
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include extended storage time in an ultra-frozen state. AstraZeneca/COVISHIELD information removed. 	June 1, 2022
Biological products MMR: Measles-Mumps-Rubella-Combined Vaccine	<ul style="list-style-type: none"> Updated indications for infants 6 months up to and including 11 months of age who are travelling. 	May 18, 2022
Biological products Polio: Polio Vaccine	<ul style="list-style-type: none"> Addition of examples of communities and specific population groups with polio. 	May 18, 2022
Biological products COVID-19 Vaccine – AstraZeneca/COVISHIELD vaccine	<ul style="list-style-type: none"> Alberta's stock of AstraZeneca expired April 30, 2022. Biological page archived and marked as no longer available. 	May 2, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> Updated to clarify 'additional' doses 	May 2, 2022
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated to include Moderna 6 to 11 years, Health Canada approved Novavax, and second booster doses. 	May 2, 2022

AIP Table of Updates

Section	Updates	Date
Immunization and COVID-19 COVID-19 Immunization: Allergy Pathways - COVID-19 Immunization for Individuals with Allergies and Other Health Conditions	<ul style="list-style-type: none"> Updated to clarify reporting requirements. 	April 26, 2022
Biological products Varicella: Varicella Vaccine	<ul style="list-style-type: none"> Included Ukrainian evacuees 13 years of age and older under exception for serology requirement to determine susceptibility. 	April 20, 2022
Biological products dTap: Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine	<ul style="list-style-type: none"> Note added for adults when polio vaccine is also indicated; diphtheria, tetanus, acellular pertussis and polio combined vaccine (dTap-IPV) should be used. 	April 20, 2022
Biological products dTap-IPV: Diphtheria-Tetanus-Acellular Pertussis Polio-Combined Vaccine	<ul style="list-style-type: none"> Due to the limited supply of IPV vaccine, dTap-IPV is the vaccine of choice for adults who require polio immunization only. 	April 20, 2022
Biological products Polio: Polio Vaccine	<ul style="list-style-type: none"> Added indication for polio vaccine for individuals identified as Ukrainian evacuees. Due to the limited supply of IPV vaccine, dTap-IPV is the vaccine of choice for adults who require polio immunization only 	April 20, 2022
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Updated to clarify guidance on suggested interval between previous COVID-19 infection and COVID-19 immunization 	April 12, 2022
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Included link to 'COVID-19 Immunization for Individuals with Allergies and Other Health Conditions.' 	April 12, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Included link to 'COVID-19 Immunization for Individuals with Allergies and Other Health Conditions.' 	April 12, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate second booster dose eligibility and additional dose eligibility for travel purposes 	April 12, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate second booster dose eligibility and additional dose eligibility for travel purposes 	April 12, 2022
Biological products COVID-19 Vaccine – Novavax (Nuvaxovid) Recombinant protein, adjuvanted	<ul style="list-style-type: none"> February 17, 2022- licensed for use in Canada April 12, 2022 - implemented in Alberta 	April 12, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> Updated eligibility to include Moderna vaccine for individuals 6-11 years of age Updated to incorporate second booster dose eligibility. 	April 12, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine 6-11 years	<ul style="list-style-type: none"> New biological page for Moderna vaccine licensure for 6-11 year olds. 	April 12, 2022

AIP Table of Updates

Section	Updates	Date
Immunization and COVID-19 COVID-19 Immunization: Allergy Pathways - COVID-19 Immunization for Individuals with Allergies and Other Health Conditions	<ul style="list-style-type: none"> New resource for health care practitioners to provide guidance and recommendations for allergies related to COVID-19 vaccine. 	April 12, 2022
Biological products MMR-Var: Measles-Mumps-Rubella-Varicella Combined Vaccine	<ul style="list-style-type: none"> Updated to align with SOT and HSCT immunization guidelines – MMR-Var is not indicated or recommended for SOT and HSCT as there is limited data on the use of MMR-Var vaccine in these groups. 	March 15, 2022
Biological products Meningococcal: Meningococcal B Multicomponent Recombinant Vaccine	<ul style="list-style-type: none"> Spacing updated from 8 weeks to 4 weeks between doses for individuals 2 years of age and older in pre-exposure schedule as per product monograph. 	March 15, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include all individuals 12-17 years of age 	March 14, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include all individuals 12-17 years of age 	March 14, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> Updated booster dose eligibility to include all individuals 12-17 years of age 	March 14, 2022
Immunization goals and rates for Alberta Immunization Goals and Objectives	<ul style="list-style-type: none"> Updated to incorporate national immunization goal of 95% for hepatitis B vaccine for children by 2 years of age. 	March, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate NACI interim guidance on suggested interval between previous COVID-19 infection and COVID-19 immunization 	March 2, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Updated to incorporate NACI interim guidance on suggested interval between previous COVID-19 infection and COVID-19 immunization 	March 2, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate NACI interim guidance on suggested interval between previous COVID-19 infection and COVID-19 immunization 	March 2, 2022
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated to incorporate NACI interim guidance on suggested interval between previous COVID-19 infection and COVID-19 immunization 	March 2, 2022
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Updated to incorporate NACI interim guidance on suggested interval between previous COVID-19 infection and COVID-19 immunization 	March 2, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> Updated to incorporate Novavax. 	March 2, 2022

AIP Table of Updates

Section	Updates	Date
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to incorporate Novavax. 	March 2, 2022
Immunization and COVID-19 COVID-19 Immunization: Defining Fully Immunized – COVID-19	<ul style="list-style-type: none"> Update to incorporate licensure of Novavax in Canada. 	March 2, 2022
Biological products Rabies: Rabies Vaccine	<ul style="list-style-type: none"> Clarified recommendation for individuals being assessed for pre-exposure rabies vaccine reporting undocumented rabies immunization series. 	February 28, 2022
Immunization and COVID-19 Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization	<ul style="list-style-type: none"> Updated to incorporate MIS-A as a reportable AESI 	February 25, 2022
Immunization and COVID-19 COVID-19 Immunization: Vaccine Eligibility and Scheduling – COVID-19	<ul style="list-style-type: none"> New resource for health care practitioners to summarize eligibility and schedules for the different vaccines, conditions, ages, and booster doses. 	February 14, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate NACI recommendation on re-immunization following myocarditis Clarified wording on individuals with history of COVID-19 infection. Adolescents 12 to 17 years of age with underlying health conditions and immunocompromising conditions eligible for a booster dose. First Nations, Metis and Inuit Individuals 12 to 17 years of age eligible for a booster dose 	February 14, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate NACI recommendation on re-immunization following myocarditis Clarified wording on individuals with history of COVID-19 infection. Adolescents 12 to 17 years of age with underlying health conditions and immunocompromising conditions eligible for a booster dose. First Nations, Metis and Inuit Individuals 12 to 17 years of age eligible for a booster dose. 	February 14, 2022
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Clarified wording on individuals with history of COVID-19 infection. 	February 14, 2022
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Clarified wording on individuals with history of COVID-19 infection. 	February 14, 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Updated to incorporate NACI recommendations for children 5-11 years of age with certain immunocompromising conditions to receive a three dose primary series. 	February 14, 2022
Immunization and COVID-19 COVID-19 Immunization: Medical Exemption Policy	<ul style="list-style-type: none"> Updated to remove Restrictions Exemption Program Reference. 	February 14, 2022

AIP Table of Updates

Section	Updates	Date
Adverse Events – Immunization Federal Vaccine Injury Support Program Information	<ul style="list-style-type: none"> New policy outlining the Vaccine Injury Support Program implemented in Canada December 2020 and is delivered independently of the Federal Government, with funding from the Public Health Agency of Canada. 	February 8, 2022
Special situations for immunization Immunization for Child SOT	<ul style="list-style-type: none"> Updated to include COVID-19 vaccine. 	February 8, 2022
Special situations for immunization Immunization for Adult SOT	<ul style="list-style-type: none"> Updated information for spacing for COVID-19 vaccine between dose 2 and dose 3. 	February 8, 2022
Special situations for immunization Immunization for Children HSCT	<ul style="list-style-type: none"> Updated to include COVID-19 vaccine. 	February 8, 2022
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Updated information for spacing for COVID-19 vaccine between dose 2 and dose 3. Updated to include COVID-19 vaccine boosters (4th dose) 	February 8, 2022
Immunization and COVID-19 COVID-19 Immunization: Defining Fully Immunized – COVID-19	<ul style="list-style-type: none"> Updated to incorporate WHO approved Covovax and Novavax vaccines. 	February 7, 2022
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated to incorporate WHO approved Covovax and Novavax vaccines. Information added for those who receive a third dose of a WHO approved vaccine. 	February 7, 2022
Biological products Herpes Zoster: Herpes Zoster – Shingrix Vaccine	<ul style="list-style-type: none"> Updated to include Health Canada approval for the prevention of herpes zoster (HZ) in individuals 18 years of age and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy 	January 2022
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include individuals 18 years of age and older with certain Immunocompromising conditions. 	January 20, 2022
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include individuals 18 years of age and older with certain Immunocompromising conditions. 	January 20, 2022
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include individuals 18 years of age and older with certain Immunocompromising conditions. 	January 20, 2022
Immunization and COVID-19 Reason codes by immunization phases for COVID-19 vaccine	<ul style="list-style-type: none"> Updated to include reason code for children 5 to 11 years of age. 	January 2022
Biological products Botulism: Botulism Antitoxin Heptavalent Types A to G	<ul style="list-style-type: none"> Updated storage and handling section. 	December 22, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Interval for third (booster) doses changed from at least 6 months to at least 5 months after last dose of the primary series for all individuals 18 years of age and older. 	December 22, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> Updated wording with respect to shortened intervals. 	December 22, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Interval for third (booster) doses changed from at least 6 months to at least 5 months after last dose of the primary series for all individuals 18 years of age and older. 	December 21, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Interval for third (booster) doses changed from at least 6 months to at least 5 months after last dose of the primary series for all individuals 18 years of age and older. 	December 21, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Interval for third (booster) doses changed from at least 6 months to at least 5 months after last dose of the primary series for all individuals 18 years of age and older. 	December 21, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated wording with respect to interchangeability. 	December 17, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated wording with respect to interchangeability. 	December 17, 2021
Immunization and COVID-19 Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization	<ul style="list-style-type: none"> Updated case definition for adenopathy related to mRNA vaccines. 	December 17, 2021
Adverse Events – Immunization Adverse Events Following Immunization Policy for Alberta Immunization Providers	<ul style="list-style-type: none"> Updated case definition for adenopathy related to mRNA vaccines. 	December 16, 2021
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Updated information under MMR and COVID-19 vaccine. 	December 16, 2021
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated to incorporate considerations and recommendations for pediatric 5 to 11 year vaccine errors or deviations. 	December 15, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Expanded booster dose eligibility for health care workers. 	December 15, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Expanded booster dose eligibility for health care workers. 	December 15, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Expanded booster dose eligibility for health care workers. 	December 15, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Individuals with a contraindication to currently available COVID-19 vaccines can receive Janssen COVID-19 vaccine with a minimum of 28 days from any previously received COVID-19 vaccine. 	December 8, 2021
Immunization and COVID-19 COVID-19 Immunization: Defining Fully Immunized – COVID-19	<ul style="list-style-type: none"> Updated to include interchangeability of Sinovac, Sinopharm, and Covaxin. 	December 6, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include all adults 18 years of age and older in a phased approach starting with those 60 years of age and older. 	December 3, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include all adults 18 years of age and older in a phased approach starting with those 60 years of age and older. 	December 3, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated booster dose eligibility to include all adults 18 years of age and older in a phased approach starting with those 60 years of age and older. 	December 3, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer Pediatric 5 to 11 years	<ul style="list-style-type: none"> November 19, 2021 - licensed for use in Canada November 26, 2021 - implemented in Alberta 	November 23, 2021
Pfizer BioNTech COVID-19 Vaccine Adult and Pediatric Comparison Table	<ul style="list-style-type: none"> New document/resource providing comparison of Pfizer BioNTech COVID-19 vaccine – Adult formulation and Pediatric 5 to 11 year formulation. 	November 23, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to include preferential recommendation for Pfizer-BioNTech COVID-19 vaccine for individuals 12 years to 29 years of age due to a lower risk of myocarditis following immunization with the Pfizer-BioNTech vaccine compared to Moderna in this age group. Interval between dose 1 and dose 2 updated to align with NACI's recommended optimal spacing of 8 weeks. 	November 23, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to include preferential recommendation for Pfizer-BioNTech COVID-19 vaccine for individuals 12 years to 29 years of age due to a lower risk of myocarditis following immunization with the Pfizer-BioNTech vaccine compared to Moderna in this age group. Interval between dose 1 and dose 2 updated to align with NACI's recommended optimal spacing of 8 weeks. 	November 23, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to incorporate Pfizer-BioNTech Pediatric 5 to 11 years COVID-19 Vaccine (mRNA) vaccine. 	November 23, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated the “Other Considerations” section to state that individuals with a history of lab confirmed COVID-19 infection who have no contraindications can be provided COVID-19 vaccine as soon as their isolation period is over. 	November 19, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated the “Other Considerations” section to state that individuals with a history of lab confirmed COVID-19 infection who have no contraindications can be provided COVID-19 vaccine as soon as their isolation period is over. Licensed use updated as per November 9, 2021 product monograph – booster doses licensed for 18 years and older. 	November 17, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Added immunocompromised individuals to the list of those eligible for a full (0.5 mL, 100 mcg) third dose. Updated the “Other Considerations” section to state that individuals with a history of lab confirmed COVID-19 infection who have no contraindications can be provided COVID-19 vaccine as soon as their isolation period is over. Licensed use updated as per November 12, 2021 product monograph – booster doses licensed for 18 years and older. 	November 17, 2021
Immunization and COVID-19 COVID-19 Immunization: Defining Fully Immunized – COVID-19	<ul style="list-style-type: none"> Updated to incorporate Covaxin (WHO approved COVID-19 vaccine). 	November 15, 2021
Immunization and COVID-19 COVID-19 Immunization: Medical Exemption Policy	<ul style="list-style-type: none"> Note added under the “Medical Deferral” section that states [Note: Individuals who have COVID-19 infection can be immunized as soon as their isolation period is over. Medical deferrals are not required]. 	November 12, 2021
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Available for use in Alberta November 12, 2021. updated to include recommendation for booster dose of mRNA vaccine 6 months following single dose 	November 12, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated ‘third dose’ eligibility to include individuals 70 years of age and older, FNMI 18 years of age and older, individuals who received a viral vector vaccine series, and HCWs with an interval of less than 8 weeks between dose 1 and dose 2 	November 8, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated ‘third dose’ eligibility to include individuals 70 years of age and older, FNMI 18 years of age and older, individuals who received a viral vector vaccine series, and HCWs with an interval of less than 8 weeks between dose 1 and dose 2 Third (booster) dose for individuals less than 65 years of age 0.25 mL (50 mcg). 	November 8, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated ‘third dose’ eligibility to include individuals 70 years of age and older, FNMI 18 years of age and older, individuals who received a viral vector vaccine series, and HCWs with an interval of less than 8 weeks between dose 1 and dose 2 	November 8, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to incorporate Janssen vaccine. 	November 5, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – Janssen	<ul style="list-style-type: none"> Janssen vaccine licensed for use in Canada March 5, 2021. 	November 5, 2021
Special situations for immunization Immunization for Adult SOT	<ul style="list-style-type: none"> Updated to incorporate COVID-19 vaccine. 	November 3, 2021
Special situations for immunization Immunization for Children HSCT	<ul style="list-style-type: none"> Updated to incorporate COVID-19 vaccine. 	November 3, 2021
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Updated to incorporate COVID-19 vaccine. 	November 3, 2021
Immunization and COVID-19 Reason codes by immunization phases for COVID-19 vaccine	<ul style="list-style-type: none"> Updated to include travel and research codes. 	October 21, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to specify the minimum interval between monoclonal antibodies/convalescent plasma used for treatment of COVID-19 infection and COVID-19 vaccines. 	October 21, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to specify the minimum interval between monoclonal antibodies/convalescent plasma used for treatment of COVID-19 infection and COVID-19 vaccines. 	October 21, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated to specify the minimum interval between monoclonal antibodies/convalescent plasma used for treatment of COVID-19 infection and COVID-19 vaccines. 	October 21, 2021
Immunization and COVID-19 COVID-19 Immunization: Defining Fully Immunized – COVID-19	<ul style="list-style-type: none"> New document/resource defining fully immunized. 	October 7, 2021
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated recommendations for co-administration of COVID-19 vaccines with all other vaccines. 	October 6, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated 'third dose' eligibility to include individuals 75 years of age and older and FNMI people 65 years of age and older. Updated recommendations for co-administration of COVID-19 vaccines with all other vaccines. 	October 6, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated 'third dose' eligibility to include individuals 75 years of age and older and FNMI people 65 years of age and older. Updated recommendations for co-administration of COVID-19 vaccines with all other vaccines. 	October 6, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated 'third dose' eligibility to include individuals 75 years of age and older and FNMI people 65 years of age and older. Updated recommendations for co-administration of COVID-19 vaccines with all other vaccines. 	October 6, 2021

AIP Table of Updates

Section	Updates	Date
Immunization and COVID-19 COVID-19 Immunization: Medical Exemption Policy	<ul style="list-style-type: none"> New policy outlining conditions that constitute a medical exemption from COVID-19 immunization in the context of the Restrictions Exemption Program 	September 23, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to add immunocompromising conditions eligible for an additional dose of COVID-19 vaccine. 	September 20, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to add immunocompromising conditions eligible for an additional dose of COVID-19 vaccine. 	September 20, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated to add immunocompromising conditions eligible for an additional dose of COVID-19 vaccine. 	September 20, 2021
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated to include additional doses for travel. Updated to include licensure of Moderna to 12 years and up. Updated to include co-administration of COVID-19 vaccine and inactivated vaccine. 	September 10, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include change to -90°C (from -80°C). 	September 8, 2021
Immunization and COVID-19 COVID-19 Immunization: Prefilled Syringes Policy	<ul style="list-style-type: none"> Updated to extend to end of March 2022. 	September 8, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Update to include additional doses for immunocompromised, residents in senior congregate living facilities and for travel. 	August 30, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to include licensure for individuals 12 to 17 years of age Update to include additional doses for immunocompromised, residents in senior congregate living facilities and for travel. 	August 30, 2021
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated recommendation for those that received their first dose of Moderna vaccine at 16 or 17 years of age. Changed from “Offer second dose of Moderna vaccine” to “Offer second dose of Pfizer vaccine.” 	July 16, 2021
Immunization and COVID-19 Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization	<ul style="list-style-type: none"> Reporting timeframe for myocarditis changed from 7 days to 42 days. 	July 16, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Removed scheduling information for extended interval (4 months) between dose 1 and 2 and exceptions for extended interval. 	July 7, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate safety information from Health Canada on myocarditis. Removed scheduling information for extended interval (4 months) between dose 1 and 2 and exceptions for extended interval.. 	July 6, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated to incorporate safety information from Health Canada on myocarditis. Removed scheduling information for extended interval (4 months) between dose 1 and 2 and exceptions for extended interval. 	July 6, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHIELD vaccine	<ul style="list-style-type: none"> Updated to incorporate safety information from Health Canada on capillary leak syndrome (CLS). 	June 30, 2021
Biological products Influenza: Influenza Vaccine Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated for 2021/2022 Influenza season. 	June 2021
Biological products Influenza: Influenza Vaccine High Dose Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated for 2021/2022 Influenza season. 	June 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated interchangeability section. 	June 16, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated interchangeability section. 	June 16, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated storage and handling for Moderna thawed vaccine. Clarified onward transportation processes for ultra frozen and frozen vaccines. 	June 15, 2021
Immunization and COVID-19 Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization	<ul style="list-style-type: none"> Updated to incorporate case definition for myocarditis. Thrombosis with Thrombocytopenia Syndrome (TTS) reporting timeframe extended to 42 days. 	June 15, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Spacing between administration of COVID-19 vaccine and other vaccines changed to 14 days (from 28 days). Removed recommendation to delay pregnancy by 28 days or more after the administration of COVID-19 vaccine 	June 14, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated storage and handling for thawed vaccine. Including information on U.S. packaging. Spacing between administration of COVID-19 vaccine and other vaccines changed to 14 days (from 28 days). Removed recommendation to delay pregnancy by 28 days or more after the administration of COVID-19 vaccine 	June 14, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Monitoring period for VITT updated to 42 days (change from 28 days). Spacing between administration of COVID-19 vaccine and other vaccines changed to 14 days (from 28 days). Removed recommendation to delay pregnancy by 28 days or more after the administration of COVID-19 vaccine. 	June 14, 2021
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> Updated WHO link. Updated recommendation for individuals who have received COVID-19 vaccine outside of Canada or U.S. 	June 14, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated VITT rates, VITT symptom list, and interchangeability section. 	June 3, 2021
Immunization and COVID-19 Management of COVID-19 vaccine administration errors and deviations	<ul style="list-style-type: none"> New resource for health professionals. 	June 3, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Exceptions to extended interval expanded to include individuals with chronic kidney disease on peritoneal dialysis or hemodialysis. 	May 31, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Exceptions to extended interval expanded to include individuals with chronic kidney disease on peritoneal dialysis or hemodialysis. 	May 31, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Exceptions to extended interval expanded to include individuals with chronic kidney disease on peritoneal dialysis or hemodialysis. Updated recommendations on second dose schedule and vaccine product. 	May 31, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated onward transportation information. 	May 31, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to include storage of thawed undiluted vials at 2°C to 8°C from 5 days to 31 days 	May 20, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include storage of thawed undiluted vials at 2°C to 8°C from 5 days to 31 days 	May 20, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Licensure updated to include individuals 12 to 15 years of age. Updated considerations for pregnancy and lactation. 	May 4 and 5, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Updated considerations for pregnancy and lactation. 	May 4, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Updated to include an additional indication - may be offered to individuals 30 years of age and older living or working in areas with high rates of transmission with approval from the Government of Alberta. 	April 30, 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Eligibility to include unlicensed use in children 12 to 15 years of age in select circumstances. Exceptions to extended dose interval to include SOT, HSCT, individuals with malignant hematologic disorders and non-hematologic malignant solid tumors receiving specific types of active treatment, and individuals on anti-CD20 monoclonal antibodies. (April 23, 2021) 	April 27, 2021
Immunization and COVID-19 Reason codes by immunization phases for COVID-19 vaccine	<ul style="list-style-type: none"> Updated to incorporate 12 to 15 years of age 	April 27, 2021
Immunization and COVID-19 Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization	<ul style="list-style-type: none"> Updated to incorporate new Thrombosis with Thrombocytopenia Syndrome (TTS) to assist with identifying VITT cases. Adenopathy – addition of timeframe specifically for mRNA COVID-19 vaccines Change of timeframe for AESI – coagulation disorder to 28 days. 	April 26, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Exceptions to extended dose interval to include SOT, HSCT, individuals with malignant hematologic disorders and non-hematologic malignant solid tumors receiving specific types of active treatment, and individuals on anti-CD20 monoclonal antibodies. 	April 23, 2021
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> Exceptions to extended dose interval to include SOT, HSCT, individuals with malignant hematologic disorders and non-hematologic malignant solid tumors receiving specific types of active treatment, and individuals on anti-CD20 monoclonal antibodies. 	April 23, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Onward transportation of thawing/thawed increased from 6 to 10 hours for Pfizer and Moderna. 	April 26, 2021
Biological products Rotavirus: Rotavirus Vaccine	<ul style="list-style-type: none"> Rotarix® to replace RotaTeq® for infants initiating a rotavirus vaccine series starting May 1, 2021. 	April 19, 2021
Immunization and COVID-19 COVID-19 Immunization: Prefilled Syringes Policy	<ul style="list-style-type: none"> Updated to extend to end of September. 	April 13, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Updated to include -25°C to -15°C storage alternative 	April 13, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include -25°C to -15°C storage alternative 	April 13, 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Scheduling information for extended interval (4 months) between dose 1 and 2. 	March 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Scheduling information for extended interval (4 months) between dose 1 and 2. 	March 2021

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine – AstraZeneca/COVISHILED vaccine	<ul style="list-style-type: none"> AstraZeneca/COVISHIELD COVID-19 vaccine licensed February 26 in Canada. 	March 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Addition of AstraZeneca to policy. 	March 2021
Immunization and COVID-19 COVID-19 Immunization: Prefilled Syringes Policy	<ul style="list-style-type: none"> New resource 	February 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Recommended spacing considerations between COVID-19 vaccine and tuberculin skin testing 	February 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Recommended spacing considerations between COVID-19 vaccine and tuberculin skin testing 	February 2021
Biological products Tuberculin PPD	<ul style="list-style-type: none"> Recommended spacing considerations between COVID-19 vaccine and tuberculin skin testing 	February 2021
Special situations for immunization Immunization of Adult SOT Candidates and Recipients	<ul style="list-style-type: none"> dTap replacing Td for routine Adult immunization. 	February 2021
Adverse Events – Immunization Adverse Events Following Immunization Policy for Alberta Immunization Providers	<ul style="list-style-type: none"> Updated to include SIRVA 	February 2021
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Scheduling information for extended interval between dose 1 and 2 included. Recommendations for immunocompromised, pregnancy and breastfeeding updated. Addition of other considerations section. 	January 14, 2021
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Scheduling information for extended interval between dose 1 and 2 included. Recommendations for immunocompromised, pregnancy and breastfeeding updated. Addition of other considerations section. 	January 14, 2021
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to include 'onward transportation' of Pfizer and Moderna COVID-19 vaccines. 	January 7, 2021
Immunization and COVID-19 Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization	<ul style="list-style-type: none"> Policy for active surveillance of AEFIS following COVID-19 immunization and for case definitions and reporting of adverse events of special interest to COVID-19 vaccine. This is a supplement to the current vaccine storage and handling policy. 	December 28, 2020
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Updated to incorporate Moderna frozen vaccine. 	December 28, 2020

AIP Table of Updates

Section	Updates	Date
Biological products COVID-19 Vaccine (mRNA) – Moderna frozen vaccine	<ul style="list-style-type: none"> Moderna COVID-19 vaccine licensed December 23 in Canada. 	December 28, 2020
Immunization and COVID-19 Alberta Vaccine Storage and Handling for COVID-19 Vaccine	<ul style="list-style-type: none"> Policy specific for unique storage and handling requirements of Pfizer COVID-19 vaccine. This is a supplement to the current vaccine storage and handling policy. 	December 16, 2020
Biological products COVID-19 Vaccine (mRNA) – Pfizer ultra frozen vaccine	<ul style="list-style-type: none"> Pfizer BioNTech COVID-19 vaccine licensed December 8 in Canada. 	December 14, 2020
Biological products MMR-Var: Measles-Mumps-Rubella-Varicella Combined Vaccine	<ul style="list-style-type: none"> Schedule change: Second dose of MMR-Var moved from 4 years of age to 18 months of age. 	January 2021
Biological products MMR: Measles-Mumps-Rubella-Combined Vaccine	<ul style="list-style-type: none"> Schedule change: Second dose of MMR moved from 4 years of age to 18 months of age. 	January 2021
Biological products Varicella: Varicella Vaccine	<ul style="list-style-type: none"> Schedule change: Second dose of Varicella moved from 4 years of age to 18 months of age. 	January 2021
Immunization schedules Routine Childhood Immunization Schedule	<ul style="list-style-type: none"> Schedule change: Second dose of MMR-Var moved from 4 years of age to 18 months of age. 	January 2021
Immunization schedules Infants: Routine Immunization Schedule	<ul style="list-style-type: none"> Schedule change: Second dose of MMR-Var moved from 4 years of age to 18 months of age. 	January 2021
Biological products dTap: Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine	<ul style="list-style-type: none"> dTap replacing Td for routine Adult immunization. 	January 2021
Biological products Td: Diphtheria-Tetanus Combined Vaccine	<ul style="list-style-type: none"> dTap replacing Td for routine Adult immunization. 	January 2021
Biological products Td: Tetanus Post-exposure Prophylaxis in Injury/Wound Management	<ul style="list-style-type: none"> Updated to remove specific referencing to Td. 	January 2021
Biological products Td: Tetanus Immune Globulin	<ul style="list-style-type: none"> Removed requirement for consultation with the local Medical Officer of Health 	January 2021
Immunization schedules Adult Immunization Schedule	<ul style="list-style-type: none"> dTap replacing Td for routine Adult immunization. 	January 2021
General principles Occupational Immunization Considerations	<ul style="list-style-type: none"> Updated to remove specific referencing to Td. 	January 2021
Biological products Herpes Zoster: Herpes Zoster – Shingrix Vaccine	<ul style="list-style-type: none"> Provincially funded and implemented for solid organ transplant recipients 18 years of age and older. 	September 2021

AIP Table of Updates

Section	Updates	Date
Special situations for immunization Immunization of Specific Populations (Immunosuppressed and Chronic Health Conditions)	<ul style="list-style-type: none"> Reviewed with expert group to clarify recommendations for congenital immunodeficiency states and immunosuppressive therapy. 	August 2020
Special situations for immunization Immunization for Children HSCT	<ul style="list-style-type: none"> MMR-Var is not indicated or recommended as there is limited data on the use of MMR-Var vaccine in this group. General updates as recommended by Alberta infectious disease and HSCT Physicians and Canadian Immunization Guide. 	August 2020
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Incorporated recommendations for Shingrix® provided by Alberta infectious disease and HSCT Physicians. General updates as recommended by Alberta infectious disease and HSCT Physicians and CIG. 	August 2020
Special situations for immunization Immunization for Children Expecting SOT before 18 Months of Age	<ul style="list-style-type: none"> MMR-Var is not indicated as there is limited data on the use of MMR-Var vaccine in this group. Univalent varicella vaccine has been shown to be safe and effective in carefully selected pediatric renal and liver transplant recipients >1 year post-transplant receiving minimal immune suppression. In consultation with the transplant physician, univalent varicella vaccine may be administered to those who were not optimally immunized prior to transplant Recommend two doses age appropriate MMR and Varicella vaccine if time permits pre-transplant. 	August 2020
Special situations for immunization Immunization for Children Expecting SOT after 18 Months of Age	<ul style="list-style-type: none"> MMR-Var is not indicated or recommended as there is limited data on the use of MMR-Var vaccine in this group. Univalent varicella vaccine has been shown to be safe and effective in carefully selected pediatric renal and liver transplant recipients >1 year post-transplant receiving minimal immune suppression. In consultation with the transplant physician, univalent varicella vaccine may be administered to those who were not optimally immunized prior to transplant Recommend two doses age appropriate MMR and VZ if time permits pre-transplant. 	August 2020
Special situations for immunization Immunization for Adult SOT	<ul style="list-style-type: none"> Incorporated recommendations for Shingrix® provided by Alberta infectious disease and Solid Organ Transplant Physicians. 	August 2020
Biological products Varicella: Varicella Zoster Immune Globulin	<ul style="list-style-type: none"> Recommendation for post HSCT updated and clarified. 	August 2020

AIP Table of Updates

Section	Updates	Date
Biological products Meningococcal: Meningococcal B Multicomponent Recombinant Vaccine	<ul style="list-style-type: none"> Booster dose recommended for those who remain on eculizumab (Soliris®). 	August 2020
Biological products Varicella: Varicella Vaccine	<ul style="list-style-type: none"> Clarified minimum spacing recommendations. Updated contraindications to note possible exception for Child SOT recipients. 	August 2020
Biological products HPV: Human Papillomavirus Vaccine	<ul style="list-style-type: none"> Expanded age eligibility to include males and females up to and including 26 years of age. 	July 2020
Special situations for immunization Immunization for Adult HSCT	<ul style="list-style-type: none"> Expanded age eligibility for HSCT individuals to include males and females up to and including 26 years of age. 	July 2020
Biological products Influenza: Influenza Vaccine Quadrivalent Inactivated	<ul style="list-style-type: none"> Updated for 2020/2021 Influenza season. 	June 2020
Biological products Influenza: Influenza Vaccine High Dose Trivalent Inactivated	<ul style="list-style-type: none"> Updated for 2020/2021 Influenza season. 	June 2020
General principles Assessment Expected Prior to Vaccine Administration	<ul style="list-style-type: none"> Updated recommendation for spacing between MMR and RhIg. Women who receive RhIg and are non-immune to rubella should receive MMR vaccine three months after the RhIg. If there is a risk of exposure to rubella disease; or pregnancy in the immediate post-partum period (3 months), the vaccine should be administered as soon as possible after delivery and then repeated at the appropriate interval. 	January 2020
Immunization schedules Adult Immunization Schedule	<ul style="list-style-type: none"> Updated to provide consistency on minimum spacing between doses of varicella vaccine. 	December 2019
Biological products Rabies: Rabies Vaccine	<ul style="list-style-type: none"> Intradermal (ID) administration will be the preferred route for post-exposure rabies vaccine with the exception of immunocompromised. 0.1 mL each at two anatomical sites (for a total of 0.2 mL). Series may be completed using a mixed IM/ID schedule as long as the scheduling is maintained. Updated vaccine stability. The vaccine, once opened must be used as soon as possible and within 6 hours. This is a change from 1 hour. Updated post-exposure schedule for previously immunized individuals. 0.1 mL ID at one anatomical site (Day 0 and 3). 	October 2019
Biological products Rabies: Rabies Immune Globulin	<ul style="list-style-type: none"> Clarified recommended interval between live vaccines and administration of RIG. 	October 2019

AIP Table of Updates

Section	Updates	Date
Biological products DTaP-IPV-Hib dTap-IPV Polio	<ul style="list-style-type: none"> Removed reference to DTaP-IPV as product is no longer available in Canada (as of July 2017). 	August 2019
Special situations for immunization Immunization for Children Expecting Solid Organ Transplant after 18 Months of Age	<ul style="list-style-type: none"> Removed reference to DTaP-IPV as product is no longer available in Canada (as of July 2017). 	August 2019
Immunization schedules: <ul style="list-style-type: none"> Routine Immunization Schedule School Immunization Schedule 	<ul style="list-style-type: none"> Updated to incorporate change to two-dose schedule for hepatitis B vaccine for students 11 to 15 years of age (effective August 1, 2019). 	July 2019
Biological products Rotavirus: Rotavirus Vaccine	<ul style="list-style-type: none"> Not contraindicated for individuals with cystic fibrosis or who screen positive for cystic fibrosis. Infants born to HIV infected mothers can safely receive rotavirus vaccine. 	July 2019
Biological products Immune Globulin (IG): Immune Globulin (Human)	<ul style="list-style-type: none"> Updated NACI recommendations for measles post-exposure prophylaxis for susceptible contacts who are pregnant or immunocompromised weighing 30 kg or more. Susceptible contacts who are pregnant or immunocompromised and 30 kg or more will not receive measles antibody concentrations that are considered to be fully protective from IMIG (maximum dose 15 mL). Susceptible-individuals excluding infants, pregnant or immunocompromised are no longer routinely recommended to receive IG following measles exposure. 	July 2019
Biological products Rabies: Rabies Immune Globulin	<ul style="list-style-type: none"> Updated to incorporate focus on infiltration of wound as per WHO guidelines. Incorporated increase in concentration of HyperRAB® product. Changed from 150 IU/mL to 300 IU/mL. 	May 2019
Biological products Rabies: Rabies Vaccine	<ul style="list-style-type: none"> Updated resources 	May 2019
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	<ul style="list-style-type: none"> Two-dose schedule for students 11 to 15 years of age (effective July 2019). Updated pre-immunization serology recommendations. Included recommendation for completing schedules for hyporesponsive individuals if the same vaccine product is not available. 	May 2019
Special situations for immunization Hepatitis B (HBVD) Algorithm for Chronic Renal Disease	<ul style="list-style-type: none"> Updated to incorporate clarity for previously immunized individuals with renal diseases. 	May 2019

AIP Table of Updates

Section	Updates	Date
Adverse Events – Immunization Adverse Events Following Immunization Policy for Alberta Immunization Providers	Updated criteria for the following reportable events: <ul style="list-style-type: none"> Allergic Reaction - changed from 0-72 hours to 0-48 hours Convulsions – changed from 5-30 days (MMR) and 5-42 42 days (Varicella) to 5-14 days (live vaccines) GBS (Guillain-Barre syndrome) – changed from 0-8 weeks to 0-6 weeks. Thrombocytopenia – changed from 0-4 weeks to 0-6 weeks. 	May 2019
Biological products Meningococcal: Meningococcal B Multicomponent Recombinant Vaccine	<ul style="list-style-type: none"> Updated to incorporate change of licensed use information. Updated scheduling for pre-exposure use. Included recommendation for use in post-exposure in previously immunized individuals. 	May 2019
Biological products Botulism: Botulism Antitoxin Heptavalent Types A to G	Incorporated requirements around storage/handling specific to this product. Special Access Program forms no longer required.	January 2019
Policy for Pharmacists Providing Pneumococcal Polysaccharide 23 Valent Vaccine	<ul style="list-style-type: none"> Pneumo-P 23 becomes available at pharmacies for healthy individuals aged 65 and older. 	January 2019
Biological products DTaP-IPV-Hib-HB: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus influenza type b Conjugate Combined Vaccine	Clarified schedule for infants with a birth weight less than 2000 grams.	January 2019
Biological products HIB: Haemophilus influenza type b Conjugate Vaccine	Incorporated catch-up schedule for HIB.	January 2019
Biological products MMR-Var: Measles-Mumps-Rubella-Varicella Combined Vaccine	<ul style="list-style-type: none"> Incorporated recommendations for children with history of febrile seizures. Minimum spacing between MMR and/or varicella containing vaccines updated. MMR-Var vaccine no longer contraindicated for HSCT recipients as per CIG. 	January 2019
Biological products Polio: Polio Vaccine	Updated recommendations from WHO for OPV doses given on or after April 1, 2016. According to the World Health Organization, as of April 2016, trivalent oral polio vaccine (OPV) was replaced with either bivalent or monovalent OPV. In order to ensure protection against all 3 poliovirus types, any doses of OPV received on or after April 1, 2016, are not considered as a valid dose within the routine Alberta Immunization Schedule. Therefore, individuals presenting with a record of OPV received on or after this date will require re-immunization with IPV or IPV-containing vaccine for any of these doses.	January 2019

AIP Table of Updates

Section	Updates	Date
Biological products Tuberculin: Tuberculin PPD	Updated to align with current Canadian standards.	January 2019
Biological products Varicella: Varicella Zoster Immune Globulin	May be offered up to 10 days post-exposure to modify varicella disease.	January 2019
Special situations for immunization Immunization for Child HSCT	<ul style="list-style-type: none"> Updated dosing and scheduling of hepatitis B vaccine for hyporesponsive individuals. MMR-Var vaccine no longer contraindicated for HSCT recipients as per CIG. 	January 2019
Immunization schedules: ▪ Adult Immunization Schedule	Updated to incorporate recommendation to offer dTap in every pregnancy as of January 1, 2019.	December 2018
Immunization schedules: ▪ Routine Immunization Schedule ▪ Infants Routine Immunization Schedule ▪ School Immunization Schedule	Immunization schedules updated to incorporate s. 18.5 of the Public Health Amendment Act which states: “A health practitioner who performs an immunization shall comply with (a) the most recent version of an immunization schedule published by the Chief Medical Officer, or (b) the part of the most recent version of an immunization schedule published by the Chief Medical Officer that is identified by the Chief Medical Officer as being mandatory.”	December 2018
Adverse event following immunization policy and procedures Adverse Events Following Immunization Policy for Alberta Immunization Providers	Updated to align AEFI policy with requirements as per Immunization Regulation .	December 2018
Vaccine Storage and Handling Management (formerly Cold Chain Management Policy and Procedures): Alberta Vaccine Storage and Handling Policy for Provincially Funded Vaccine (formerly Alberta Vaccine Cold Chain Policy)	Updated to align reporting and documentation of temperature excursions (cold chain breaks) with requirements as per Immunization Regulation .	December 2018
Biological products MMR-Var: Measles Mumps Rubella-Varicella Combined Vaccine	MMR-Var recommended for HSCT recipients.	December 2018
Biological products dTap: Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine	Updated to include recommendation to offer dTap in every pregnancy. For implementation January 1, 2019.	November 2018

AIP Table of Updates

Section	Updates	Date
<p>Introduction</p> <p>AIP Background:</p> <ul style="list-style-type: none"> Federal leadership <p>Provincial Mandate:</p> <ul style="list-style-type: none"> legislative authority and provincial leadership <p>Eligibility Criteria for Provincially Funded Vaccine</p> <p>Roles and Responsibilities:</p> <ul style="list-style-type: none"> delivery of childhood immunization in Alberta immunization opportunities responsibilities of immunization providers 	<p>Introduction of the AIP reorganized and updated. Eligibility Criteria for Provincially Funded vaccine is new.</p> <p>Roles and Responsibilities – updated.</p>	October 2018
<p>General principles</p> <ul style="list-style-type: none"> Assessment Expected Prior to Vaccine Administration Biological Considerations 	<p>General Principles - Assessment Expected Prior to Vaccine Administration and Biological Considerations replaces General Immunization guidelines and Contraindications and Precautions.</p>	October 2018
<p>Biological products</p> <p>MMR: Measles-Mumps-Rubella Combined Vaccine</p>	<p>MMR – updated to incorporate post-exposure recommendations for infants 6 to 11 months of age.</p>	October 2018
<p>Biological products</p> <p>Botulism: Botulism Antitoxin Heptavalent (Equine) Types A to G</p>	<p>Botulism – updated to incorporate revised product monograph.</p>	October 2018
<p>Biological products</p> <p>Hepatitis B Vaccine</p>	<p>Routine school immunization schedule for Hepatitis B changed from being offered in grade 5 to grade 6.</p>	September 2018
<p>Biological products</p> <p>Human Papillomavirus Vaccine: HPV9</p>	<ul style="list-style-type: none"> The routine school immunization program for HPV vaccine changed from being offered in Grade 5 to Grade 6. Updated to incorporate two-dose scheduling for individuals 9 to 14 years of age who are immunocompetent and non HIV infected. 	September 2018
<p>Biological products</p> <p>Varicella Vaccine</p>	<ul style="list-style-type: none"> Children with a verbal history of chicken pox disease are eligible to receive varicella-containing vaccine as they present in child health clinic (i.e., children born August 1, 2012, or later). Clarified immunization recommendations for HCWs 	September 2018
<p>Biological products</p> <p>Influenza: Influenza Vaccine Quadrivalent Inactivated</p>	<ul style="list-style-type: none"> Updated for 2018/2019 Influenza season. Influenza Vaccines for 2018-2019 season: Fluzone®, Flulaval® Tetra 	August 2018
<p>Biological products</p> <p>Pneumococcal: Pneumococcal Vaccine, 13-valent Conjugate</p>	<p>Clarified eligibility for individuals with malignant solid organ tumors and long term immunosuppression.</p>	August 2018

AIP Table of Updates

Section	Updates	Date
Biological products Pneumococcal: Pneumococcal Vaccine, 23- valent Polysaccharide	Clarified eligibility for individuals with cancer and past history of cancer.	August 2018
Biological products Td/TdP: Tetanus Immune Globulin	Updated to include minimum spacing between doses.	August 2018
Immunization schedules: School Immunization Schedule	Updated to incorporate two-dose scheduling for HPV 9 for individuals 9 to 14 years of age who are immunocompetent. Implementation is September 2018 for school immunization program.	July 2018
Biological products Td/TdP: Tetanus Post-exposure Prophylaxis in Injury/Wound Management	Updated to include minimum spacing between TIG doses.	July 2018
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	Updated dosing and scheduling for hyporesponsive individuals under 16 years of age. <ul style="list-style-type: none"> • Engerix®-B –3 doses using 1.0 mL [20 µg] (change from 4 dose using 0.5 mL [10 µg]). • Recombivax HB® - 3 doses using 1.0 mL [10 µg] (change from 3 doses using 0.5 mL [5 µg]). 	July 2018
Biological products Meningococcal: Meningococcal Conjugate (Groups A,C,Y and W-135) Vaccine	Updated Nimenrix® licensed use - starting at 6 weeks of age (change from 12 months of age).	July 2018
Adverse event following immunization policy and procedures Adverse Events Following Immunization Policy for Alberta Immunization Providers	Updated reporting criteria for 'Other Severe or Unusual Events': Requires emergency room visit within 72 hours of immunization added for which there is no other known cause.	July 2018
Immunization schedules: Routine Immunization Schedule Infants Routine Immunization Schedule Infants Beginning Immunization at 4 Months of Age or Later	Immunization schedules updated to incorporate change to Rotavirus vaccine schedule.	April 2018
Biological products Rabies: Rabies Vaccine	Removed reference to rabies pre-exposure form and link to form. As of January 1, 2018, this form does not need to be submitted to Alberta Health.	April 2018

AIP Table of Updates

Section	Updates	Date
Biological products MMR-Varicella: Measles Mumps Rubella- Varicella Combined Vaccine	Updated to include NACI recommendations for varicella proof of immunity: verbal history is not a reliable indicator of immunity in populations where varicella vaccine has been introduced. This recommendation will be phased in starting with children 12 months up to and including 6 years of age as they present for immunization.	April 2018
Biological products MMR: Measles Mumps Rubella Combined Vaccine	Updated rubella indications to include adults born before 1957 generally presumed to have immunity to rubella.	April 2018
Biological products Varicella: Varicella Vaccine	Updated to include NACI recommendations for varicella proof of immunity: verbal history is not a reliable indicator of immunity in populations where varicella vaccine has been introduced. Immunization recommendation for 2 doses of varicella containing vaccine will be phased in starting with the following four groups: children 12 months up to and including 6 years of age, women identified through routine prenatal screening, health care workers (HCW) upon hire, and post-secondary HCW students as they present for immunization.	April 2018
Biological products Rotavirus: Rotavirus Vaccine	Updated to include RotaTeq® which will be used for infants initiating a rotavirus vaccine starting May 1, 2018. RotaTeq® series is three-doses whereas Rotarix® is two-doses.	April 2018
Biological products HPV: Human Papillomavirus Vaccine	Updated to incorporate two-dose scheduling for individuals 9 to 14 years of age who are immunocompetent. Implementation is September 2018 for school immunization program.	April 2018
Biological products DTaP-IPV-Hib-HB: Infanrix hexa®	<ul style="list-style-type: none"> Expand indications to include hepatitis B vaccine as Universal Infant Hepatitis B program for infants born March 1, 2018, or after. (Infanrix-hexa® replaces Pediacel® and Infanrix®-IPV/Hib). Updated to include post-immunization serology recommendations for infants born to infected mothers and infants who are a household contact of a hepatitis B case or carrier. 	March 2018
Special situations for immunization Immunization of Specific Populations	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes.	February 2018
Special situations for immunization Principles of Immunization in HSCT and SOT Recipients	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes.	February 2018
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	<ul style="list-style-type: none"> Individuals with inflammatory bowel disease who will be on long term immunosuppressive medications eligible for hepatitis B vaccine. Individuals born in 1981 or later who would have been eligible for the school universal hepatitis B program and who have not received a series of hepatitis B vaccine are eligible for hepatitis B vaccine. 	February 2018

AIP Table of Updates

Section	Updates	Date
Special situations for immunization Immunization for Child HSCT	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes. <ul style="list-style-type: none"> • People awaiting HSCT should not receive varicella-containing vaccine. • All HSCT recipients, regardless of GVHD, should receive both vaccines Pneumo-C-13 and Pneumo-P-23 (adults and children). • Consider 1 dose MMR and then check serology. If no seroconversion, give 2nd dose if needed 3 or more mos after 1st dose. 	February 2018
Special situations for immunization Immunization for Adult HSCT	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes. <ul style="list-style-type: none"> • People awaiting HSCT should not receive varicella-containing vaccine. • All HSCT recipients, regardless of GVHD, should receive both vaccines Pneumo-C-13 and Pneumo-P-23 (adults and children). • Consider 1 dose MMR and then check serology. If no seroconversion give 2nd dose if needed 3 or more mos after 1st dose. 	February 2018
Special situations for immunization Immunization for Child Expecting SOT before 18 months of Age	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes. <ul style="list-style-type: none"> • Screen for measles, mumps, rubella, and varicella 6 weeks post immunization. 	February 2018
Special situations for immunization Immunization for Child Expecting SOT after 18 months of Age	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes. <ul style="list-style-type: none"> • Screen for measles, mumps, rubella, and varicella 6 weeks post immunization. 	February 2018
Immunization goals and rates for Alberta Immunization Goals and Objectives	Immunization goals updated to be consistent with revised National guidelines.	January 2018
Special situations for immunization Immunization of Adult SOT Candidates and Recipients	Guidelines were reviewed by expert working group. Updated for clarity and to incorporate wording changes. <ul style="list-style-type: none"> • Screen for measles, mumps, rubella, and varicella 6 weeks post immunization. 	February 2018
Biological products Hepatitis B (HBV): Hepatitis B Vaccine	Incorporated updated CIG guidelines for individuals at high risk: recommend a documented series for those with only verbal history who are anti-HBs positive and recommend a complete second series if anti-HBs negative after first series.	November 2017
Biological products Pneumococcal: Pneumococcal Vaccine, 13-valent Conjugate	Addition of nephrotic syndrome as indication for eligibility in adults as per CIG. Clarification of scheduling for healthy and high risk children.	November 2017
Biological products DTaP-IPV-Hib-HB: Infanrix hexa®	Expand indications to include hepatitis B vaccine as Universal Infant Hepatitis B program for infants born March 1, 2018, or after.	November 2017
Biological products Immune Globulin: Immune Globulin (Human)	Updated to incorporate change in dose recommended in Hepatitis A post-exposure as per Grifols Therapeutics Inc. change in prescribing Information and MMWR.	November 2017

AIP Table of Updates

Section	Updates	Date
Biological products HPV: HPV 9	Expanded eligibility to include MSM 17 to 26 years of age as per NACI recommendation.	October 2017
Biological products Td/TdP: Tetanus Post-exposure Prophylaxis in Injury/Wound Management	Incorporated management of tetanus-prone wounds for infants younger than 6 months of age who have not received a full three dose primary series of tetanus toxoid-containing vaccine.	September 2017
Biological products dTap vaccine	Included recommendations for immunization of contacts of diphtheria cases and carriers of diphtheria.	September 2017
Biological products Influenza Vaccine: ▪ Fluzone® ▪ Fluad®	Influenza Vaccines - Updated for 2017-2018 Influenza season.	July 2017
Biological products DTaP-IPV-HIB: Infanrix®-IPV/Hib Pediacel®	Pediacel® and Infanrix®-IPV/Hib implemented for use in place of DTaP-IPV as both Quadracel® and Infanrix®-IPV are currently unavailable.	June 2017
Introduction Immunization Goals and Objectives	Rotavirus added - by 12 months of age 80% of children will have received two doses of rotavirus vaccine.	June 2017
Biological products MMR: Measles Mumps Rubella Combined Vaccine	Adults born in or after 1970 eligible for 2 doses of mumps-containing vaccine.	June 2017
Cold chain management AVCC Policy	Alberta Vaccine Cold Chain Policy updated.	March 2017
Adverse event following immunization policy and procedures Adverse Events Following Immunization Policy for Alberta Immunization Providers	Adverse Events Following Immunization Policy for Alberta Immunization Providers updated.	December 2016
Biological Products Td Polio: ▪ Td Polio Adsorbed	Updated to reflect changes to Polio indications.	November 16, 2016
Biological Products Polio Vaccine: ▪ Polio: Imovax®	Routine Adults - Due to the limited supply of polio vaccine and the low risk of exposure to polio in Alberta and Canada – the recommendation for the routine immunization of unimmunized adults is suspended until further notice. Health Care Workers - Primary series and single lifetime reinforcement for HCWs who may be exposed to patients excreting polio. Travelers to 'Polio Emergency Countries' - Exporting and/or infected with polio and staying 4 weeks or longer. Primary series and reinforcing dose for adults. http://polioeradication.org/polio-today/polio-now/public-health-emergency-status/	November 16, 2016

AIP Table of Updates

Section	Updates	Date
Biological Products Rabies Vaccine: <ul style="list-style-type: none"> ▪ Imovax® ▪ RabAvert® 	Recommendations included for post-exposure series initiated in another country: <ul style="list-style-type: none"> • If the post-exposure series initiated meets the World Health Organization (WHO) approved vaccine, was administered I.M., and meets WHO approved schedule - complete the series as appropriate. RIG can be offered if the client has not already received RIG and it can be administered within seven days of the first dose of I.M. rabies vaccine. • For uncertain vaccines, vaccines given I.D., or unknown schedule, including no clear documentation - restart series and offer RIG. 	November 16, 2016
Biological products DTaP-IPV-HIB: <ul style="list-style-type: none"> ▪ Infanrix®-IPV/Hib ▪ Pediacel® 	Pediacel® revised to include off-license use of infants 6 weeks of age and older. Both Pediacel® and Infanrix®-IPV/Hib updated to reflect current off license use of vaccine for HSCT clients including adults.	September 21, 2016
Biological products Human Papillomavirus Vaccine: HPV 9	Gardasil® 9 - Implementation of HPV 9 for school program.	September 1, 2016
Biological products Influenza Vaccine: <ul style="list-style-type: none"> ▪ Fluzone® ▪ Fluad® ▪ Flumist® 	Influenza Vaccines - Updated for 2016-2017 Influenza season. Flumist® <ul style="list-style-type: none"> • Removed preferential recommendation for 2 to 17 years of age. • Removed egg-allergic individuals as a contraindication. 	August 29, 2016
Biological products Hepatitis B Vaccine: <ul style="list-style-type: none"> ▪ Engerix®-B ▪ Recombivax HB® 	Incorporated updated recommendations from CIG and ACIP for immune compromised individuals and those with renal disease. <ul style="list-style-type: none"> ▪ Recommendation that these individuals who are antiHBs negative after first series receive a second series followed by serology one month later. Included schedule for infants born to HBsAg negative mothers weighing less than 2000 grams who received Hepatitis B vaccine at birth. <ul style="list-style-type: none"> ▪ Neonates weighing less than 2,000 grams who received their first dose of hepatitis B vaccine at birth should receive three additional doses of vaccine administered at 1, 2, and 6 months of age. 	August 25, 2016
Biological products Hepatitis B Immune Globulin (HBIG)	Updated to be consistent with CIG, Red Book and ND guidelines for indications for HBIG. <ul style="list-style-type: none"> ▪ Removed under indications for HBIG: Infants younger than 12 months of age whose primary caregiver is infected with hepatitis B. ▪ Note: this does not include infants born to hepatitis B infected mothers. The indication for HBIG remains. 	August 25, 2016

AIP Table of Updates

